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LEGAL DEVELOPMENTS 
GLOBALIZATION OF BIOTECHNOLOGY AND THE 
PUBLIC HEALTH CHALLENGES ACCOMPANYING IT 
Michael J. Malinowskt 
I. INTRODUCTION 
The Human Genome Project (HGP) has drawn together the global 
biomedical science community by introducing a common prize-a 
map of the human genome to serve as a shared resource for 
scientists throughout the next millennium.1 By doing so, HGP has 
focused the community's efforts, energy, and resources; it also has 
intensified competition among researchers, institutions, and 
countries. This combination of increased focus and c ompetition has 
generated remarkable advances in biomedical science and technology 
development, and d rawn billions of investment funds from the 
• Copyright 1996 by Albany Law Review and Michael J. Malinowski, JD (Yale Law School), 
BA (Tufts University). Associate, Kirkpatrick & Lockhart LLP (Boston); Law and Science 
Research Faculty, The Eunice Kennedy Shriver Center for Mental Retardation. The opinions 
expressed are the author's unless attributed to others. An earlier draft of this Article was 
presented in July 1996 at the Joint Meetings of the Law and Society Association and the 
Research Committee on Sociology of Law in Glasgow, Scotland, and this Article has benefitted 
from those who shared their responses and suggestions. Special appreciation is due Christine 
Motta, Laura Silva and the editors of the .Afbany Law Review, Pat Jones (Feinstein Partners 
Inc.), Michaela Mahon (De Facto Consultants Ltd.), Mike Wort (Genus Communications), and 
Ian Leslie (Scottish Ent.erprise Operations) for being invaluable sources of information and 
sharing time, contacts, and research materials. Thanks also to Robin J.R. Blatt, Peter 
Mclsaac, Maureen O'Rourke, and Lucia Silecchia for their helpful suggestions, Dylan Black for 
his research contribution, and Diane Raysan and Kirkpatrick & Lockhart for supporting this 
project. 
1 See generally ROBERT COOK-DEEGAN, THE GENE WARS 148-60 (1994) (discussing the 
emergence of HGP, including its scientific, political, and ideological background); Robert M. 
Cook-Deegan, Origins of the Human Genome Project, 5 RISK: HEALTH, SAFETY & ENV'T. 100 
(1994) (reporting on the origins and progression of HGP); Michael J. Malinowski & Maureen 
A. O'Rourke, A False Start? The Impact of Federal Policy on. the Genotechnology Industry, 13 
YALE J. REG. 163, 190-93 (1996) (addressing the goals of HGP and its effect on the biotech 
industry). 
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private sector in a remarkably brief period of time. 2 The result is 
a burgeoning global industry with a myriad of products in various 
stages of development. The biotechnology3 industry's first full 
generation of therapeutics and diagnostics now is reaching the world 
markets, and these products are simply the first drops from an 
immense pipeline of promising research and development (R&D) 
efforts.4 The market for biotechnology products, which reached $8. 7 
billion in 1995,5 is expected to exceed $100 billion by the year 
2000.6 According to many experts, "the 21st century ... will be the 
century of biological science. "7 
The commercialization of genetic technologies, such as HGP, is 
accompanied by global challenges. One such immediate and 
profound challenge is determining the manner of reviewing and 
2 See generally KENNETH B. LEE, JR. & G. STEVEN BURRILL, BIOTECH 96: PuRSUING 
SUSTAINABILITY, ERNST & YOUNG'S TENTH .ANNuAL RE.PORT ON THE BIOTECH INDUSTRY 9-25 
(1995) (commenting on the amount of capital raised through public offerings, private 
placements, and venture capital funding); EUROPEAN BIOTECH 96: VOLATILITY AND VALUE, 
ERNST & YOU NG'S THIRD ANNuAL REPORT ON THE EUROPEAN BIOTECH INDUSTRY 23-31 (1996) 
[hereinafter EUROPEAN BIOTECH 96) (reporting on product approvals, development highlights, 
capitalization rates, and investment activities of biotech companies); Malinowski & O'Rourke, 
supra note 1, at 165-67 (detailing genotech discoveries of recent years attributed primarily to 
investments by the private sector and academia); Jennifer Lanthier, Agricultural Biotech Seen 
as a Tough Sell on Wall Street, FIN. POST, June 13, 1996, at 3 ("Of the US$ [sic] 2.4 billion 
invested in 1994 in technology companies, the biggest single chunk, US$ [sic] 973 million, went 
to life sciences companies like pharmaceutical firms ; . .  with another US$ [sic] 1 billion split 
between software and information technology companies."). 
3 Biotechnology is a broad term that bridges several scientific disciplines and encompasses 
genotechnology (the commercial applications of genetic science, also known as genomics), 
biopharmaceuticals, bioremediation, and bioagriculture. See MICHAEL A. EPSTEIN, MODERN 
INTELLECTUAL PROPERTY§ 11.01 (3d ed. 1995) (defining biotechnology broadly as to include 
"genetics, molecular biology, biochemistry" and other disciplines); Malinowski & O'Rourke, 
supra note 1, at 165 n. l. This Article focuses on the commercial biotechnology industry which, 
at the present time, is largely concentrated in genotechnology. See generally BIO 96 
INTERNATIONAL BIOTECHNOLOGY MEETING & ExlnBITION, LlvE VIDEO CONFERENCE, GENOMICS: 
IMPACT ON HEALTH CARE (June 11, 1996) (on file with author) [hereinafter GENOMICS] 
(discussing various aspects of genomics, including therapeutics, gene expression, intellectual 
property, and ethical issues). 
4 See generally LEE & BURRILL, supra note 2, at 19-28 (detailing product successes, disap­
pointments, and promising possibilities for the future); EUROPEAN BIOTECH 96, supra note 2, 
at 16-21 (highlighting product developments and approvals for 1995); Malinowski & O'Rourke, 
supra note 1, at 174-80 (attributing drug developments likely to be available to the public in 
the near future to science and entrepreneurialism). 
5 See LEE & BURRILL, supra note 2, at 9. 
8 See Ian Lang Launche� Bio�chnology Crusade to Take Britain Into the 21st Century, M2P�
, .June 19� 1996, 
available in. 1996 WL 10345783 [hereinafter Biotechnolog y  Crusade] (surmising that [b]y the year 2000 the world market for biotechnology products is expected to reach ... 70 billion [British pounds]"). 
7 EUROPEAN BIOTECH 96, supra note 2, at ii. 
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regulating innovative biotechnology-based diagnostics8 and 
therapeutics in order to maximize public health benefits, minimize 
delay for those who could benefit from them, and promote efficacious, 
responsible, and safe use. Another is determining how the deluge of 
·new health care capabilities is going to be financed and made 
generally available to those in need of the technologies.9 This 
second problem is particularly troublesome in light of the fact that 
modern medicine already is capable of doing much more than society 
is willing to pay for collectively through group or national health 
insurance.10 The success of biotechnology, as marked by the 
introduction of innovative products into commerce, will exacerbate 
health care finance and allocation problems; price-prohibitive health 
insurance and rationing are realities that pre-date the widespread 
commercialization of biotechnology. 11 
This Article addresses these challenges in the context of the health 
care systems of the United States (U.S.) and the United Kingdom 
(U.K.) which have begun to facilitate the growth of significant 
biotechnology industries.12 These countries also hold considerable 
influence over regulatory review and approval of genetic diagnostics 
and therapeutics in the major world markets. An overarching 
premise of this Article is that the U.S. and the U.K. could maximize 
8 This challenge is exemplified by the controversy in the United States (U.S.) surrounding 
the availability of presymptomatic genetic testing services to detect the presence of variations 
of genes called BRCAl and BRCA2 ("breast cancer 1" and "breast cancer 2") that have been 
linked to breast and ovarian cancer. See generally Michael J. Malinowski & Robin J.R. Blatt, 
Commercialization of Genetic Testing Services: The FDA. Market Forces, and Biological Tarot 
Cards, 71 TuL. L. REV. (forthcoming 1997) (manuscript at 1-7, 36-40, on file with the Afbany 
Law Review). A Task Force assembled by the Ethical, Legal and Social Issues (ELSI) Working 
Group of HGP has issued written principles, in draft form, that recognize the scientific 
shortcomings of existing presymptomatic genetic testing technology and the dangers of making 
such tests widely available outside of the major research institutions. See TASK FORCE ON 
GENETIC TESTING OF THE NIH-DOE WORKING GROUP ON ETHICAL, LEGAL, AND SOCIAL 
IMPLICATIONS OF HUMAN GENOME RESEARCH, DRAFT INTERIM PRINCIPLES (Fe b. 1996) 
[hereinafter TASK FORCE); see also Joan Stephenson, Questions on Genetic Testing Services, 274 
JAMA 1661, 166 1 (1995) (noting that, as genes related to diseases like breast cancer are 
discovered, laboratories rush to diagnose these diseases through genetic testing and to assess 
who is at risk). 
9 See generally Michael J. Malinowski, Capitation, Advances in Medical Technology, and the 
Advent of a New Era in Medical Ethics, 22 AM. J. L. & MED. 331, 337-47 (1996) [hereinafter 
New Era] (addressing this dilemma in the context of the U.S. healthcare system). 10 See id. at 332. 11 See id. at 343-44. See also Part II (discussing biotechnology in the United States (U.S.) 
and the United Kingdom (U.K.)). 12 See LEE & BURRILL, supra note 2, at 43-45 (breaking down the U.S. biotech industry by 
region and year of founding); EUROPEAN BIOTECH 96, supra note 2, at 4 (illustrating that the 
U.K. has the largest biotech industry in the European Union (E.U.) by a considerable margin). 
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the public health benefits of biotechnology by collaborating on 
responses ·to the shared challenges of financing and regulat!ng 
commercialization of biotechnology . In other words, the Article 
proposes that, in order to maximize the health benefits of biotech­
nology, the U.S. and the U.K. approach the public health challenges 
accompanying the commercialization of biotechnology with the same 
collaboration embodied in HGP. Even if this approach were only 
partially as successful in the regulatory and commercial arenas as it 
has been in the field of biomedical science, it would reduce transac­
tion costs by: {1) eliminating duplication; {2) enabling the U.K. to 
benefit from the industry experience of the U.S.; (3) allowing the U.S. 
to benefit from the health care allocation experience of the U.K.; (4) 
hastening the introduction of needed health policy and other 
regulatory infrastructure; (5) improving the quality of that 
infrastructure; and (6) eliminating unnatural barriers to industry 
collaboration between the U.S. and the U.K. in the fie�d of biotech­
nology. The latter would enable the best science in both countries to 
be developed commercially, thus maximizing the public health 
benefits of biotechnology on a global scale. 
Part II presents an overview of the biotechnology industries in the 
U.S. and the U.K. Trends and recent advances in the development 
of these industries are identified and discussed. Part III addresses 
two profound challenges accompanying the commercialization of 
biotechnology. First, this section fully discusses the review and 
regulation of innovative biotech diagnostics and therapeutics by 
focusing on the increasing responsiveness of the Food and Drug 
Administration (FDA) to biotechnology and the impact of the recently 
established European Medicines Evaluation Agency (EMEA) on the 
U.K. industry. Second, Part III addresses the impact of the 
forthcoming generation of genetic technologies on health care finance 
resources. Lastly, Part III concludes that, while the capabilities of 
modem medicine are on the verge of increasing dramatically, the 
need to ration and make more "tragic choices" will prevent some 
from enjoying its benefits. 13 
Part IV sets forth proposals both for regulating the commer­
cialization of biotechnology and for responding to the public health 
challenge of financing health care in an age of rapid expansion in 
medical capabilities. These proposals generally arise from the 
observation that globalization of biotechnology and the challenges 
13 See generally GUIDO CALABRESI & PHlLIP BOBBl'M', TRAGIC CHOICES 17-28 (1978) 
(introducing discussion of the societal allocation of scarce resources). 
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accompanying it raise the importance of comparative analysis and 
collaboration between the U.S. and the U.K. on several levels. 
Although grounded in actual regulation and industry insight, the 
analysis presented also embodies law and economics theory.14 
II. BIOTECHNOLOGY IN THE U.S. AND THE U.K. 
Biotechnology has become a major U.S. industry in "a remarkably 
brief period of time. "15 The incorporation of most biotechnology 
companies post-dates HGP, as does substantial venture capital and 
other investment in the industry. 16 In fact, although HGP did not 
commence until 1990, the U.S. biotechnology sector has matured into 
an industry with commercial products, powerful multinational 
pharmaceutical investors and allies, and enough organization to 
effectuate significant FDA reforms.17 This accomplishment is 
underscored by America's long-standing and infamous ten to twelve 
year lab-to-market drug lag.18 In March 1995; approximately 
14 This analysis is grounded in fundamental law and economic principles identified and 
discussed by Richard A. Posner and his contemporaries. See generally ROBERT COOTER & 
THOMAS ULEN, LAW AND ECONOMICS 1-55 (1986) (pointing out, by way of examples, that legal 
rules deemed just and economic approaches adopted for efficiency reasons often lead to the 
same conclusions); RICHARD A. POSNER, ECONOMIC ANALYSIS OF LAW 3-17, 19-26 (3d ed. 1986) 
(providing relevant chapters entitled The Nature of Economic Reasoning and The Economic 
Approach to Law). However, the focus of the analysis is international economic law (IEL), 
which increasingly is being recognized as an independent theoretical approach. See generally 
infra Part IV. 
16 Malinowski & O'Rourke, supra note 1, at 170 (discussing accomplishments such as the 
identification of gene sequences and the market viability achieved by genotech companies). 
16 Industry-wide investment from the multinational pharmaceutical industry did not begin 
until the second half of 1995. See LEE & BURRILL, supra note 2, at 10-13 (commenting upon 
the dearth of venture capital funding in the early part of 1995); Malinowski & O'Rourke, supra 
note 1, at 180 n.90 (describing how the genotech industry's funding has shifted from 
government grants to commercial investments). 
17 See generally, Malinowski & O'Rourke, supra note 1, at 165, 188, 210-12 (mentioning 
annual sales in the billions for the past few years and predicting sales of new products without 
market substitutes and investment from pharmaceutical companies will continue to rise in the 
future due to FDA reforms designed to accelerate approval times). 18 See Stephen A. Bent & Paul M. Booth, ICH Sets Standards for Drug Developers, NAT'L 
L.J., July 8, 1996, at Cl; Stephen D. Moore, Fast Relief' Drug Companies Find EU Approval 
System Eases Path to Market, WALL ST. J. (Eur.), May 6, 1996, at 1 [hereinafter Fast Relief]. 
It is too early to assess the extent to which recent FDA reforms will shorten this time lag, and 
many other reforms have been proposed that could reduce it further. See Jeffrey L. Fox, 
''Nitty-Gritty" FDA Guidelines Wanted Sooner Not Later, 14 NATURE BIOTECHNOLOGY 698 
(1996) ("Officials of the ... [FDA] have publicly promised that efforts both to simplify the 
regulation of well-characterized biotechnology products and to harmonize agency procedures 
will be completed by late summer."); see also BILL CLINTON & AL GoRE, REINVENTING 
REGULATION OF DRUGS AND MEDICAL DEVICES (Apr. 1995) [hereinafter REINVENTING 
REGULATION] (outlining the Clinton Administration's proposals for self-reform); Mark Guidera, 
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twenty-five biotechnology drugs had reached the market. 19 That 
number now exceeds forty and is increasing rapidly. 20 
Alliances be tween prestig ious non-profit resear ch 
institutions-· historically grant supported, independent, and 
aloof.-and the biotech industry have become commonplace. 21 In 
fact even the most renowned non-profit institutions engaged in 
bio�edical R&D (for example, the Massachusetts Institute of 
Technology, Massachusetts General Hospital, and Johns Hopkins 
University) have aggressive technology transfer offices that are 
actively seeking out such partnerships. 22 Although the annual 
budget of the National Institutes of Health (NIH) was relatively 
unscathed during last year's budget cuts,23 the trend in the U.S. has 
Optimism Greets FDA Reforms; Biotech Firms Predict Easier Medicine Trials, THE SUN 
(Baltimore), Nov. 19, 1995, at lE ("[B]iotechnology executives ... are breathing a lot easier 
these days about such big up-front investments now that the Food and Drug Administration 
has revamped a host of regulations governing the industry."). These reforms include proposals 
to: (1) eliminate requirements that force companies to seek a separate license for each facility 
where they plan to manufacture a drug; (2) lessen reporting requirements for adjustments in 
the manufacturing process; (3) eliminate the requirement that each batch of a biotech­
developed drug be sent to the FDA for testing; (4) impose a 30-day deadline for the FDA to 
respond to a company that has submitted additional information requested after the FDA has 
put a clinical trial on hold; and (5) introduce more flexibility and cooperation with industry. 
See id. See also REINVENTING REGULATION, supra, at 32-37; Fox, supra, at 698. Variations of 
these proposals were incorporated into the FDA Reform Bill introduced in the last session of 
Congress by Senator Kassebaum. See S. 1477, 104th Cong. (1996); Robert Pear, Lawyers and 
Lobbyists Help Guide Effort by Republicans to Speed Drug Approvals, N.Y. TIMES, Mar. 4, 
1996, at Al5 ("Republicans on the Senate Committee on Labor and Human Resources and the 
House Commerce Committee, joined by some Democrats, have concluded that Congress must 
revise the F.D.A. laws to give patients swifter access to new drugs and devices."). For a 
discussion of FDA Commissioner Kessler's denial of the need for such extensive reform, see 
infra note 116. 
19 See Malinowski & O'Rourke, supra note 1, at app.I n.449 (identifying biotech drugs 
approved by the FDA and their developers and manufacturers). 
20 See Lauran Neergaard, Ethics Clash with Science: How Far is Too Far in Genetic 
Engineering?, CINCINNATI ENQUIRER, June 12, 1996, at AlO ("Biotechnology is a young but fast­
growing industry, with 40 medical technologies and 21 agricultural products on the market."). 21 See Mitotix Obtains Rights to the Natural Cell Cycle Inhibitor, 10 BIOTECH PATENT NEWS 
27 (1996) (noting the grant of licenses by Memorial Sloan-Kettering Cancer Center and Fred 
Hutchinson Cancer Research Center, both non-profit, independent institutions, to Mitotix, Inc.). 
See generally infra note 194 and accompanying text. 
22 See Malinowski & O'Rourke, supra note 1, at 181-87 (noting the technology transfer 
arrangements in alliances between the genotech industry and academia). · The author has 
observed that most of these major research institutions are staffing intensely entrepreneurial 
technology �ransfer offices with the mission of seeking out allies, enabling researchers to 
develop their technology in order to add value, and properly valuing technology to finance 
re:arch �d development, all in order to realize long-term royalty revenue streams. See id. 
See id. at 203 � n.231. The 1996 budget for NIH was approximately $7 billion and the federal �vemment i? rece�t years has funded approximately 36% ofR&D in the U.S. and 70% 
of Amencan academic medical research. See id. See also Health Policy: Managing to Care, 
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been towards privatization of basic science R&D. 24 Ironically, the 
same means less in real terms, for tremendous advances in 
biomedical research are creating more grant-worthy science and 
increasing the demand for consistent funding. In addition, the 
money allotted by NIH is being spread more widely to reach more 
researchers and institutions. 25 
The British biotechnology industry is younger than its U.S. 
counterpart and lacks significant fully developed and marketed 
products.26 Overall, the U.K. biotech industry has been slower to 
emerge despite the fact that British basic science in biotech­
nology-some of the best in the world27-has been well funded by 
the Wellcome Trust, the world's largest private medical research 
foundation.28 A number of regulatory disincentives are responsible 
THE ECONOMIST (U.S.), Sept. 23, 1995, at 70; Graeme Browning, Tense Days Down in the Lab, 
27 NAT'L J. 1005 (1995) (discussing the effects of Congressional budget cuts on scientific 
research). 
24 See Malinowski & O'Rourke, supra note 1, at 191 (noting private funding outstrips public 
funds); see also supra notes 21-22 and accompanying text. 
26 See Christopher Anderson, Small Businesses to Get Bigger Slice of US Research Pie, 359 
NATURE 470, 470 (1992) (noting university scientists' displeasure with the Congressional 
decision to shift federal research funding to small businesses through the Small Business 
Innovation Research Program). 
26 See generally EUROPEAN BIOTECH 95: GATHERING MOMENTUM, ERNST & YOUNG'S SECOND 
ANNUAL REPORT OF THE EUROPEAN BIOTECH INDUSTRY 1, 11-21 (1995) [hereinafter EUROPEAN 
BIOTECH 95) (discussing biotech products launched in the U.K. and expectations for faster 
product approvals with the help of the EMEA). 
27 One of the most recent significant contributions from the U.K. is the identification by 
scientists in Edinburgh, Scotland of a gene linked to depression that could lead to much more 
effective treatment for that condition. See Nigel Hawkes, Scientists Identify Gene Linked to 
Depression, THE TIMES (London), Mar. 15, 1996, auailable in 1996 WL 6481302 (noting the 
discovery of a gene possessed by 10% of those who suffer from depression in Great Britain). 
Another significant contribution is an approach to cancer treatment that operates by "blocking 
the action of molecules known as neuropeptides, a type of hormone that also helps carry 
messages between nerve cells." New Treatment Could Offer Hope for Lung Cancer Patients, 
EDMONTON J., Apr. 17, 1996, at Al 7 (commenting on the potential to thwart cancer growth and 
facilitate recovery). 
28 See David Dickson, Wellcome Trust to Launch Transfer Company, 374 NATURE 6, 6 (1995) 
[hereinafter Transfer Company]; Ian Mundell, Wellcome Trust to Double Spending After Sale 
of Shares, 358 NATURE 359, 359 (1992) (explaining that the tremendous financial h oldings of 
the Trust are attributable to the sale of stock in Wellcome PLC, manufacturer of the AIDS 
drug AZT). R&D contributions from the Wellcome Trust rival those of the Medical Research 
Council (MRC), the U.K.'s counterpart to the NIH. See Wellcome Cash, THE ECONOMIST (U.K.), 
Apr. 6, 1996, at 58 (1996) ("The Wellcome Trust is now roughly the same size as the Medical 
Research Council, a body that allocates British government funds to biomedical research."); see 
also Peter Aldhous, Wellcome Trust: Britain's Big Biomedical Spender, 256 SCIENCE 1132 
(1992) (stating that researchers in front-line fields like molecular biology and neuroscience are 
as likely to send their proposals to Wellcome Trust as to MRC). Significant contributions by 
the Wellcome Trust to U.K. biotechnology R&D include a loan to University College, London, 
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for this restrained growth, including the inability to procure patent 
protection for genetic discoveries29 and the related unavailability of 
to purchase property for an international center for basic and clinical biotech r�'*'.arch; a grant 
to fund genome research at Cambridge; an award to fund research of genetic influences on 
common diseases, such as diabetes and asthma, at Oxford; and a gift toward the partial price 
of a new laboratory at the Institute of Neurology in London. See David Dickson, Britain's 
Wellcome Trust Stretches Its Financial Wings, 363 NATURE 102, 102-03 (1993) ("The loan ... is 
the latest in a series of moves by Wellcome that are intended to establish centres of excellence 
in biomedical research throughout Britain."). British science may become even more important 
in the future due to the efforts of the Wellcome Trust to preserve creativity: 
The Trust, a London-based charity, is not only rich, it has proven itself innovative and 
adventurous, a model for what a non-governmental organi(z]ation can do. This 
year ... the Trust is .. . offering individual researchers Pounds 50,000 ($75,000) to 
pursue their most improbable ideas. 
. . . The Trust is flexible and imaginative in its approach to funding. 
Wellcome Cash, supra, at 58. There is fear in the U.S. that creativity and objectivity in basic 
science is being lost due to the privatization of R&D. Specifically, there is concern that, rather 
than allowing researcher discretion and the raising of a general floor in science, basic science 
is being directed by corporate decisions to pursue and develop research discoveries solely 
according to their commercial viability. See, e.g. , Malinowski & O'Rourke, supra note 1, at 187 
(discussing the concern that the biotech industry's pressure to generate profits may "skew the 
course of basic science"); Christine Gorman, Has Gene Therapy Stalled?, TIME, Oct. 9, 1995, 
at 62, 62-63 (noting that, while gene therapy holds extraordinary promise, enthusiasm and 
financial pressures may have caused a premature push to market that is sacrificing basic 
science and human safety for a quick return on investment). 
29 See Malinowski & O'Rourke, supra note 1, at 200-01 (discussing how Article 53(a) of the 
European Patent Convention which "prohibits granting patents for inventions whose 
publication or exploitation would be contrary to public policy or morality," has blocked E.U. 
patent protection of genetic discoveries); see also European Parliament Blocks EU Rules on 
Patents for Biotechnology Products, 9 WORLD INTELL. PRoP. REP. 96, 96-97 (1995) (commenting 
on veto of gene patents by the European Parliament); John Richards, International Aspects of 
Patent Protection for Biotechnology, 4 FORDHAM lNTELL. PRoP. MEDIA & ENT. L. J. 433, 443-52 
(1993) (describing the guidelines of the European Patent Office). Efforts to introduce E.U. 
legislation aimed at making the E.U. biotechnology industry more competitive with its U.S. 
counterpart have been unsuccessful. See Malinowski & O'Rourke, supra note 1, at 198-200 
(discussing the controversy surrounding the patentability of gene sequences); David Dickson, 
British MPs 'Likely to Oppose Gene Patents', 373 NATURE 550, 550 (1995) (identifying "'growing 
consensus' among committee members" of the House of Commons Select Committee on Science 
and Technology that patenting DNA sequences could hinder the research of genetic disease). 
But see Gary Moss & Simon Cohen, Patents in the Public Interest ,  372 NATURE 814, 814 ( 1994) 
(stating that the European Commission recently introduced supplemental protection 
certificates (SPCs) to extend patent protection for pharmaceutical products, which could be 
particularly beneficial to biotechnology in light of delays due to "clinical trials and regulatory 
approval"). See also StefEyckmans, The Wheels are Finally Starting to Turn at the EMEA, 30 
MED. MARKETING & MEDIA 32 (1995) (noting that the birth of the EMEA will increase market 
efficiency in the field of pharmaceuticals by creating a single European market). However the 
E.U. Commission now has revised a draft directive that would create common Iegisl�tion 
throughout the E.U. for protection of biotechnology inventions. See Kerri A. Kazak. et al., 
European Union Directive on Biotechnology Inventions, 3 J. PROPRIETARY RTS. 32, 32 (Mar. 
1996). This re�sed d�ctive restates th� traditional European requirement that patents must 
be founded on mvention rather than discovery, denies patent protection to germ-line gene 
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capital. 30 Relatively strict requirements for listing on the London 
Stock Exchange (LSE),31 and the lack of a European Union (E.U.) 
equivalent to NASDAQ have augmented the latter.32 Although 
there are almost 600 biotech companies in Europe and some of the 
world's largest investors in the life sciences sector are in Europe, 
only thirty-five to forty European biotech companies have gone 
therapy, and limits the patentability of genetically modified animals to instances where 
suffering caused by the genetic modification is proportionate to the benefit derived. See id. 
Still, "members of the biotechnology industry broadly favor the revised Directive because it 
would provide certainty and stability in the protection of biotechnology inventions through the 
European Union." Id. 
so A correlation between the ability to patent scientific discoveries and the willingness of the 
private sector to invest in their commercial potential has been recognized by many, including 
Carl Feldbaum, President of the Biotechnology Industry Organization (BIO), the major U.S. 
biotechnology trade association. See Adam Marcus, Owning a Gene: Patent Pending, 2 NATURE 
MED. 729, 730 (1996) ("'About 90 percent [of BIO members] do not have products on the 
market . . . . They have to raise money to fund the research. What [investors] look for are 
intellectual property rights."') (quoting Carl Feldbaum); see also Nicholas Scott-Ram, Making 
More of Academic Assets, 364 NATURE 666, 666 (1993) (equating the U.S. biotech industry's 
success in finding funding for research and in commercializing inventions to its success with 
technology transfer associated with patent protections). This link between the availability of 
capital and patent protection also was recognized by a U.K solicitor who stated: 
With safeguards for the public already in place, everything must be done to strengthen 
the rights of patent owners and the patent system around the world. Otherwise, 
potentially crucial discoveries can be lost. For example, in countries such as those of 
Eastern Europe, where researchers rank among the best in the world, inventions cannot 
be properly exploited because the necessary infrastructure for obtaining and asserting 
patents does not exist. 
Moss & Cohen, supra note 29, at 814. 
31 See Karen Bernstein, Europe's Effort to Create a NASDAQ, BIOCENTURY, Mar. 6, 1996, 
at Al; David Dickson, Britain Urged to Lift Barriers to Investment in Biotechnology, 361 
NATURE 572, 572 (1993) [hereinafter Barriers] (stating that the LSE "places stricter demands 
on fledgling companies," such as requiring "initial investors in British companies" to maintain 
their investments until the companies show profits); Scott-Ram, supra note 30, at 666 (noting 
that the grant of intellectual property rights is a pre-requisite to become listed on the LSE). 
Other conditions for listing biotech companies on the LSE include an ability to attract funds 
from sophisticated investors; capitalization prior to listing of at least twenty million British 
pounds sterling; at least two drugs in clinical trials; corporate partnerships with one or more 
companies that have committed at least five million British pounds sterling; and R&D 
expenditures of at least twenty million British pounds sterling over three or more years. See 
Bernstein, supra, at A5. 
32 See EUROPEAN BIOTECH 96, supra note 2, at iii (looking forward to the 1996 commence­
ment of a European Exchange as a way to develop "European markets for venture capital"); 
infra notes 41-42 and accorupanying text (discussing the new exchange equivalent to 
NASDAQ); see also Organization for Economic Cooperation and Development, Venture Capital 
in OECD Countries, FIN. MARKET TRENDS, Feb. 1996, at 15, 37 (citing the ECU 21.2 billion 
that was invested in portfolio companies in comparison to the meager ECU 9.4 billion that was 
divested as an illustration of the stagnation caused by the lack of investment exit vehicles 
(meaning access to security markets) which has resulted in a "'liquidity crisis' in Europe"). 
128 Albany Law Review [Vol. 60 
public.33 In fact, "difficulties in raising venture .
ca�ital domestical­
ly . . . [have forced] small biotechnology compam�s mto the �s of 
foreign investors, particularly those from the Uruted Stat�s: 
Times are changing, however. The U.K. government has Jomed the 
· 
. "t 35 d UK U.S. in making biotechnology an econormc pnon y, an .. 
biotech companies now are able to raise money in financial markets 
in Copenhagen, London, Paris, and Vienna. 36 "On the London 
88 See Bernstein, supra note 31, at A3. 
84 Barriers, supra note 31, at 572. But see UK Firms Buy Into Drug Design Skills of US 
Start-ups, 373 NATURE 372, 372 (1995) [hereinafter Start-ups] ("Two British companies have 
taken advantage of the relatively low price of US biotechnology shares to acquire west-coast 
companies that will help their plans to use advanced computing techniques to design new 
drugs."). This buy-up of U.K. technology is not unlike the purchase of U.S. biotech R&D by 
multinational pharmaceutical companies during the lean investment years of 1994 and early 
1995. However, the U.S. industry was able to stay independent and vibrant by structuring 
alliances around specific technology, dealing with multiple pharmaceutical companies, and 
using the alliances with pharmaceutical companies to attract public investment. See 
Malinowski & O'Rourke, supra note 1, at 188-90 (identifying several of the above mentioned 
alliances and describing the benefits and problems associated with these mergers). 
86 See EUROPEAN BIOTECH 96, supra note 2, at 27, 58 ("The rest of Europe needs to wake 
up to the trends now being established in the UK market . . .. [T]here is no argument that the 
UK is currently the major site for entrepreneurial European bioscience companies."). In June 
1996, President of the Board of Trade, Ian Lang, launched "[a] major cross-Government drive 
to boost Britain's place at the forefront of global biotechnology." Biotechnology Crusade, supra 
note 6. Britain's "crusade" includes identification of ten priority areas: (1) "a world-class 
science base .. . [accompanied by] quick and effective technology transfer"; (2) a "supply 
of ... qualified scientists"; (3) "protection of intellectual property"; (4) "public confidence 
through public understanding"; (5) "a regulatory climate" that promotes both "safety" and 
"competitiveness"; (6) "open markets for biotechnology products"; (7) "attracti[on] [ofl inter­
nationally mobile investment"; (8) "a climate which promotes start-up and growth of new 
biotechnology companies"; (9) more responsiveness to biotech from "UK industry sectors"; and 
(10) "awareness" of the "strategic importance of biotechnology" and support from "European 
institutions." Id.; see Board of Trade, Fresh Challenges Unveiled to Prove Biotechnology Means 
Business, M2PW, June 18, 1996, available in 1996 WL 10345784 ("An expansion of the 
successful Biotechnology Means Business initiative was announced today by Board of Trade 
President Ian Lang."). The U.K. government also has set up a Human Genetics Commission 
to serve as a strategic body to monitor medical genetics in response to parliamentary pressure 
for a unified group with a strategic overview. See UK Sets up Human Genetics Commission, 
CLINICA, July 1996 (describing the commission as a non-statutory body consisting of eminent, 
independent experts who will report to both health and industry ministers); Dep't of Health, 
Membership of Advisory Committee on Genetic Testing, M2PW, July 10, 1996, available in 1996 
WL 10348248 (listing the members of the Advisory Committee). Within the U.K., the 
government of Scotland has been instrumental in establishing a highly organized, 
entrepreneurial effort to foster the growth of the biotechnology industry that includes providing 
seed money and facilitating procurement of venture capital from the private sector. See 
LocATE IN SCOTLAND, BIOTECHNOLOGY SCOTLAND (Spring 1996); BIOTECH SCOTLAND, 
BIOTECHNOLOGY IN SCOTLAND (Summer 1996) [hereinafter BIOTECHNOLOGY lN SCOTLAND]. 
86 See Mike Ward, Genset Sets Tone for Global Biotechnology Financing, 14 NATURE 
BIOTECHNOLOGY 810, 810 (1996) [hereinafter Genset]; LEE & BURRILL, supra note 2, at 23-31. 
Relevant country-based European securities markets include Chapter 20 of the LSE, the 
1996] Globalization of Biotechnology 129 
market alone, the combined capitalization of emerging bioscience 
companies tripled last year, to $4. 7 billion. "37 Investor interest h�s 
been rising recently and enabling the industry to mature. Shares m 
the sector rose in value thirty-nine percent during the first half of 
1996, outpacing the London market's overall gains by approximately 
forty to one.38 Favorable clinical news from the industry's leaders, 
most notably British Biotech, 39 is responsible for much of this 
recent surge in the appeal of U. K. biotechnology to investors. 40 The 
most prominent European effort to develop capital structures 
supportive of growth companies is the Brussels-based European 
Association of Securities Dealers Automated Quotation (EASDAQ), 
Alternative Investment Market (AIM) in London, and the Nouveau Marche in France. See 
Bernstein, supra note 31, at Al. This past March, Genset, a French genomics (genetics-based 
science) company, raised $86.4 million in a dual listing on NASDAQ and the Nouveau Marche, 
and Genset's market capitalization now is over $400 million. See Genset, supra, at 810. 
37 Julia Flynn, Britain's Bedazzling Biotech Stocks, Bus. WEEK (lnt1 Ed.), June 24, 1996, 
at 162E2 [hereinafter Bedazzling]; see Julia Flynn, Europe Catches Biotech Fever, Bus. WEEK 
(lnt1 Ed.), June 3, 1996, at 46 [hereinafter Biotech Fever] (noting that European investors are 
heavily investing in British Biotech). 
88 See Bedazzling, supra note 37, at 162E2; Biotech Fever, supra note 37, at 46. 
39 See Sylvia Davidson, ls British Biotech's Marimastat a Major Cancer Drug?, 14 NATURE 
BIOTECHNOLOGY 819, 819 (1996) ("On May 21, British Biotech (Oxford, UK), the UK's largest 
biotechnology company, became one of the four most highly valued biotechnology companies 
in the world."). The May 1996 disclosure by British Biotech of Phase II clinical trial results 
for its anticancer compound, Marimastat, increased the company's capital by $3 billion in just 
three days. See Bedazzling, supra note 37, at 162E2; Stephen D. Moore, British Biotech Surges 
9.4% as New Drug Passes Key Test, WALL ST. J. (Eur.), May 22, 1996, at 3 [hereinafter Biotech 
Surges] (noting that the drug is "'designed to stop or delay cancers spreading and may 
encourage normal cells to wall off the tumor'"); Daniel Green, British Biotech's Shares Soar on 
Hopes for New Cancer Drug, FIN. TIMES, May 22, 1996, at 21 [hereinafter Cancer Drug] 
("[T]rials confirmed the drug's potential for treating many 'solid tumour cancers' including 
pancreatic, ovarian, colorectal and prostate."). British Biotech's announcement also has risen 
investor interest in the entire sector and facilitated public offerings by other companies. See 
Bedazzling, supra note 37, at 162E2 (reporting that shares in Britain's bioscience industry 
have increased by 39% since January 1996); Matthew Lynn, Biotech Gets High on Hopes of 
Drug Bonanza, THE T1MEs (London), Feb. 18, 1996, available in 1996 WL 6475639 [hereinafter 
Drug Bonanza] (stating that British Biotech has "electrified the stock market" and, as Europe's 
industry leader, will impact the industry with its successes or failures); Biotech Surges, supra, 
at 3 (noting how the "investor frenzy" in British Biotech stock has encouraged other health­
related companies to invest their stock in London markets). 
40 See EUROPEAN BIOTECH 96, supra note 2, at 24-26 (attributing the growth of the U.K. 
bioscience sector largely to favorable product reports from leading companies like British 
Biotech). Besides British Biotech, industry leaders include Celltech (developing treatment for 
Croh�'s disease), Cortecs International (developing treatment for osteoporosis), and Scotia 
Holdmgs (developing cancer drugs). See Drug Bonanza, supra note 39 (noting that stock prices 
for British biotech companies have been increasing); see also Bedazzling, supra note 37, at 
162E2 (noting that "the combined capitalization of emerging bioscience companies tripled last 
year, to $4.7 billion"); Biotech Fever, supra note 37, at 46 (listing "Britain's Booming Biotech 
Stocks"). 
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which opened in September 1996. 41 EAS.
DAQ is an attempt to 
create a European version of NASDAQ, which has brought close to 
300 biotech companies to market. 42 "Experts estimate that by the 
year 2000, 22 million jobs in Europe will be affected by biotech-
nology. "43 
• • 
Despite this progress, the market appeal of U.K. b1otech is 
"strikingly volatile."44 Therefore, as has been �rue for th� 
u.�. 
biotech indust"" it is likely that there will be maJor fluctuations m • J, � 
value tied to research and regulatory events. However, beneath 
the recent British Biotech-inspired surge in market value, longer­
term economic stability for U.K. biotech should materialize from: (1) 
the escalating state of knowledge in the field of biomedical science 
world-wide and the leading role and contributions of U.K. resear­
chers;46 (2) the maturation and success of the U.S. biotechnology 
industry, which serves as a reassuring point of reference;47 (3) 
investment from and alliance agreements with multinational 
pharmaceutical companies and U.S. biotech companies, and research 
capital from venture capitalists;48 (4) the responsiveness and 
support of the British government;49 (5) encouragement of commer-
41 See Genset, supra note 36, at 810. 
42 See id. (stating that EASDAQ has already attracted much attention from those who wish 
to invest in biotech); Bernstein, supra note 31, at Al ("Until now, and for reasons that are often 
specific to each country, there has been limited private and public capital available in Europe, 
which has hindered the development of high-risk, growth-oriented sectors such as biotech."). 
4S BIOTECHNOLOGY IN SCOTLAND, supra note 35, at 10. 
44 Drug Bonanza, supra note 39 ("Earlier this month, Celltech's share price collapsed by 24% 
in a single day after it announced it was abandoning research on one of its most advanced 
asthma drugs . . . . "). 
45 See generally Malinowski & O'Rourke, supra note 1, at 216, 236 (explaining that clinical 
disappointments, expectations about new products, and regulatory policies impact not only the 
companies whose products are involved, but also effect the amount that investors are willing 
to contribute to the industry as a whole). 
� See Drug Bonanza, supra note 39 (citing headway made in U.K. laboratories and interest 
shown by the pharmaceutical giants in potential purchases and alliances with biotech 
companies as key factors leading to investor interest). 47 • See EUROP� BIOTEC� 96, supra note 2, at 30 ("The US investment community is served 
by highly expenenced buy-side and sell-side analysts who understand the risks as well as the 
opportunities."). 
48 See id. (stating that pharmaceutical interest in and alliances with the biotech industry are key factors for market appeal). 
49 See supra note 35 and accompanying text; see generally JOHN ABRAHAM, SCIENCE, POLITICS AND THE PHARMACEUTICAL INDUSTRY: CONTROVERSY AND BIAS IN DRUG REGULATION ?4-76, 255 (199?) (n�ting that the British government, after years of effective protectionism of its pharmaceutical mdustry, now is extending that protection to its biotechnology industry). 
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cialization of biotech discoveries by the Wellcome Trust;50 (6) the 
establishment in London of the EMEA, a E.U. counterpart to the 
FDA that has introduced a coordinated, centralized, and timely 
procedure for the E.U.-wide review of biotechnology and other 
innovative products;51 (7) new European market avenues for raising 
capital;52 and (8) the availability of private domestic capital which, 
relative to the U.S., has not yet been invested in biotechnology.53 
The U.S. and U.K. industries are increasingly being drawn 
together, especially through investment from and alliance 
agreements with multinational pharmaceutical companies. 54 This 
�0 The Wellcome Trust now is directly facilitating commercialization of research discoveries 
through the establishment of "a technology-transfer company to help the scientists it funds to 
find commercial outlets for the results of their research." Transfer Company, supra note 28, 
at 6. This decision was inspired by: (1) "anticipated guidelines from the Charity Commis­
sioners emphasizing that charities have a duty to ensure that the research they finance is 
properly exploited"; and (2) "complaints from many Wellcome-funded scientists in universities 
about the lack of adequate support from the technology-transfer mechanisms set up by the 
universities for which they work." Id. 61 See The European Commission Background Report on the European Medicines Evaluation 
Agency, M2PW, Jan. 31, 1995, available in 1995 WL 10419600 [hereinafter Background Report] 
(detailing the organization of the EMEA); United States Dep't of Commerce, The European 
Medicines Evaluation Agency, 95 NTISAFTECH, Apr. 15, 1995, available in 1995 WL 9230589 
[hereinafter EMEAJ (noting EMEA's goal of coordinating licensing procedures); Gina M. 
Cavalier, Pushing Parentless Pharmaceuticals: Toward an International Home for "Orphan 
Drugs" and a Cure for "Zebra" Diseases, 27 LAW & POL 'y INT'L Bus. 447, 463-64 ( 1996) 
(discussing EMEA's goal to speed up approval times without sacrificing safety); Note, FDA 
Reform and the European Medicines Evaluation Agency, 108 HARV. L. REV. 2009, 2019-21 
(1995) [hereinafter FDA Reform] (commenting on the potential effects of the EMEA on the 
FDA's regulatory system); Pharmaceuticals: "Success" in First Year for EU Medicines Agency, 
EUR. ENv'T, Feb. 20, 1996, available in 1996 WL 8759045 [hereinafter Success) (stating that 
"[b]y the end of.1995, [the EMEA's) scientific committee responsible for human medicines had 
adopted eight positive opinions on applications for marketing authori[z)ation, leading to three 
authori[z)ations before the end of the year"); Eric Reguly, Medicines Evaluation Agency 
Provides the Right Tonic, THE TIMES (London), Mar. 19, 1996, available in 1996 WL 6482054 
(stating that the EMEA is making London a world centre for pharmaceuticals, and that it may 
even emerge as a super-regulatory agency linked with the FDA and Japan). The EMEA is 
addressed fully below in Part III.A. 62 See Biotech Feuer, supra note 37, at 46 ("Now, with new bourses such as France's 
Nouveau Marche, London's Alternative Investment Market, and the launch of EASDAQ, a 
Brussels-based electronic market for high-tech startups, there could soon be more bioscience 
flotations . . . .  "). 68 See generally Bernstein, supra note 31, at Al-A2 (contrasting U.S. and European 
investment in biotech firms). 
M See Malinowski & O'Rourke, supra note 1, at 188-90; Drug Bonanza, supra note 39 ("Last 
year, Glaxo Wellcome paid $533 [million) for the American company, Affymax. Earlier, Ciba­
Geigy of Switzerland acquired 49.9% of Chiron in a deal that valued the company at $4.2 
billion. Both deals indicated that the big players were looking to buy biotech outfits as a way 
of filling gaps in their own research pipelines."). 
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trend is likely to continue.55 In the U.S. and now the U.K. , the 
entrepreneurial quality of smaller, competitive biotech companies 
built around specific science and headed by talented and driven 
researchers has proven effective for advancing the industry. 56 
Despite heavy pharmaceutical investment, the U.S. biotech industry 
has maintained its entrepreneurial quality by entering into multiple 
alliances with different entities, each around specific technology. 57 
The U.K industry should be able to do the same, especially since its 
companies have the option of entering into alliance agreements with 
mature U.S. counterparts as well as with pharmaceutical com­
panies. 58 Assuming investment capital and interest remain 
relatively constant, the availability of more potential allies could 
raise the demand for the most promising U.K. biomedical research 
and create the opportunity to negotiate for highly favorable terms. 59 
In fact, the U.K. could benefit tremendously from the U.S. 
experience and the maturation of the U.S. biotech industry. For the 
purposes of commercial policy making, strategizing, and industry 
development, collaboration is in the best interest of the U.K.60 
Through collaboration and access to the insight of seasoned U.S. 
biotech executives, the U.K. may benefit from the U.S. experience 
and avoid some of its mistakes.61 On a more fundamental level, the 
U.S. industry has raised and expended capital and dramatically 
advanced the state of biotechnology for the world. The U.K. , 
therefore, is in the enviable position of tapping domestic capital and 
66 See generally LEE & BURRILL, supra note 2, at 29-30 (describing the successes 
pharmaceutical companies have had in consolidating); EUROPEAN BIOTECH 96, supra note 2, 
at 41 ("US pharmaceutical companies are beginning to look at European countries."); id. at 15 
("The market focus of the European bioscience sector is more geared to serving large 
pharmaceutical, agrifood or chemical multinationals."). 
118 See EUROPEAN BIOTECH 95, supra note 26, at 7-9 (reporting, based on surveys compiled 
for the annual report, that seventy-five percent of biotech companies in Europe and the U.S. 
have less than fifty employees). 
67 See LEE & BURRILL, supra note 2, at 29-30; Malinowski & O'Rourke, supra note 1, at 188-
90. 
118 See EUROPEAN BIOTECH 96, supra note 2, at 41-42 (noting the interest of U.S. 
pharmaceutical and biotech companies in European companies); Mike Ward, Dramatic Growth 
Forecast for UK Biotechnology Firms, 367 NATURE 674, 674 (1994) [hereinafter Dramatic 
Growth] (stating that access to U.S. and Japanese markets, among others, is vital to the 
commercialization of U.K. biotech); see also supra note 48 and accompanying text. 
69 See Dramatic Growth, supra note 58, at 674. 
60 See id. 61 See EUROPEAN BIOTECH 96, supra note 2, at 43 ("One of the advantages European 
bioscience CEOs have is that they can learn from the experiences of their US counterparts."). 
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building a biotechnology industry with U.S. involvement.62 
Furthermore, the U.K. has the advantage of referring to the U.S. 
industry to increase credibility and confidence among investors.63 
These factors could temper the kind of market volatility that caused 
investment to dry up and a sell-off of developed biomedical science 
in the U.S. during 1994 and early 1995.64 
In sum, the U .K. biotech industry is evolving along the growth 
lines of the more mature U.S. biotech industry. Globalization 
through, among other things, multinational pharmaceutical 
investment is bringing these industries together.65 Growth and 
increased globalization of the industry in both countries is likely to 
continue, 66 and "in the future basic medical research will largely be 
confined to the biotech companies, with the stock market bearing the 
risks of success or failure, while the big drug companies will 
concentrate on the more controllable tasks of development and 
marketing."67 
III. THE IMPACT OF BIOTECHNOLOGY ON STANDARD OF CARE 
AND TREATMENT 
The biotechnology industry in the U.S. and the U.K. is undergoing 
a privatization of R&D coupled with a more supportive regulatory 
infrastructure beneficial to commercialization. 68 Among the public 
62 See id. at 41-42 (explaining that U.S. biotech and pharmaceutical companies look to 
European companies as sources of new ideas). 63 See Drug Bonanza, supra note 39 (noting that U.S. successes have built up investor 
enthusiasm); supra note 47. 
64 In the U.S., a tremendous amount of domestic capital was tapped in the early 1990s and 
used to develop biomedical science, a great deal of which was sold to the pharmaceutical 
industry when private investment began to dwindle towards the end of 1994. See Malinowski 
& O'Rourke, supra note 1, at 180-90 (mentioning pharmas, academic institutions, government, 
and private companies as sources of funding). Though pharmaceutical investment is likely to 
expedite the market approval, manufacturing, and distribution of biotechnology, some U.S. 
companies may have liquidated significant profit and growth opportunities associated with 
their first generation products in order to survive into the future. 66 See supra notes 48, 54 and accompanying text. 
66 See supra note 55 and accompanying text. 67 Drug Bonanza, supra note 39; see Matthew Lynn, Biotech Tycoon Moues into Nerue Drugs , 
THE TIMES (London), Jan. 7, 1996 (profiling Cerebrus, a biotech company "concentrat[ing] on 
doing contract research for big pharmaceutical companies," and observing that "big drug 
companies are becoming keener to contract out research as the industry consolidates and as 
they seek ways to control the rising costs of medical research and development"). 68 See supra notes 21-24 and accompanying text (discussing privatization of R&D in the 
U.S.); EUROPEAN BIOTECH 95, supra note 26, at 1 (same); infra Part III.B (addressing this 
trend in both the U.S. and the U.K.). 
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health challenges accompanying the commercialization of biotech­
nology, two are especially imme�ate an? profoun?: (1� to re�ew and 
regulate a multitude of truly mnovative genetic diagnostics and 
therapeutics to maximize public health benefits; and (2) to make the 
resulting deluge of new health care capabilities accessible to those 
likely to benefit from them. 69 The difficulty of the latter is 
underscored by the fact that limitations already have been placed on 
health care resources under both private group and nationalized 
health insurance.70 These limitations are embodied in prohibitive 
pricing and risk assessment by insurers, coverage exclusions, and 
rationing. 71 
A. The Shared Challenge of Review and Regulation 
"The products regulated by the F.D.A. account for 25 percent of the 
nation's economic output."72 Not surprisingly, the FDA has become 
increasingly responsive to biotechnology. Biotech therapeutics are 
classified biologics and subject to regulation under both the Food, 
Drug, and Cosmetic Act (FDCA)73 and the Public Health Service Act 
(PHSA). 74 While the "objective of the FDCA is to ensure the safety 
and effectiveness of the final product,"75 PHSA is focused on "'rigid 
control of the manufacturing process,' which reflects the particular 
scientific and historical characteristics of biopharmaceuticals. "76 
The effect has been an unduly burdensome number of license and 
other requirements on the manufacturers of biologics. 77 However, 
in April 1995, the FDA identified reforms that could accelerate its 
drug review process substantially, including harmonization of FDA 
standards with international scientific standards, the acceptance of 
69 See New Era, supra note 9, at 332. 
70 See id. at 331 (noting that efforts by insurers to contain costs have hindered people in 
need of services from taking advantage of advances in medical technology). 
71 See id. (discussing increased cost assessment and rationing as goals of capitation and 
suggesting safeguards are needed). 
72 Pear, supra note 18, at Al5. 
73 See 21 U.S.C. §§ 321-395 (1994); see also JAMES T. O'REILLY, FOOD AND DRUG AD­
MINISTRATION §  13.21 (2d ed. 1993); Gary E. Ga.merman, Regulation of Biologics Manufac­
turing: Questioning the Premise, 49 FOOD & DRUG L.J. 213, 213 (1994). 
74 Pub. L. No. 57-244, 58 Stat. 682, 702-03 (1944) (codified at 42 U.S.C. § · 262 ( 1994)). See 
Malinowski & O'Rourke, supra note 1, at 205-13 (discussing the regulatory climate within 
which the biotech industry operates). 
76 Malinowski & O'Rourke, supra note l, at 205. 
76 Id. at 205-06 (quoting Gary E. Gamerman, Regulation of Biologics Manufacturing: Questioning the Premise, 49 Foon & DRUG L.J. 213, 213 (1994)). 
77 See id. at 206-20. 
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a "single major clinical trial . . .  as evidence that a drug works,"78 
privatization of review for some low-risk medical devices, and 
elimination of the requirement that the FDA approve facilities 
manufacturing all biologic drugs through the Establishment License 
Application (ELA) process.79 
The FDA's responsiveness to biotechnology in recent years is due 
primarily to a combination of well-organized consumer advocacy 
groups and the election of a Republican Congress,80 coupled with 
other factors. 81 These factors include Congressional proposals for 
78 Id. at 218. 
79 See id. at 217-18; LEE & BURRILL, supra note 2, at 58; supra note 18 (discussing FDA 
reform movement). 
80 See John Schwartz, FDA Often Blamed for Problems that Aren't Agency's Fault, WASH. 
POST, July 15, 1996, at Al 7 (reporting that the Pharmaceutical Research and Manufacturers 
of America paid for approximately 140 disease victims to travel to Washington, D.C. and raise 
complaints about the FDA to members of Congress). But see Matthew Rees, What Makes 
David Kessler Run?, WKLY. STANDARD, June 3, 1996, at 25 (portraying Commissioner Kessler 
as "an amazingly resourceful political animal"). The voices· of consumer advocacy groups 
representing the victims of breast cancer and AIDS have been especially strong. See generally 
Piedmont Venture Group, Cancer Diagnostics, MEDICAL TECHNOLOGY STOCK LETTER, no. 294, 
Apr. 18, 1996 (updating progress in cancer diagnostics, including reports on biotech companies, 
imaging procedures, and blood tests); Pear, supra note 18, at A15 ("Within days after the 
Republicans won control of Congress in 1994, some gay rights groups saw an opportunity to 
win speedier access to new, unapproved treatments for AIDS by rewriting Federal drug laws."). 
This strategy appears to be working as the FDA has already dramatically expedited approval 
of drugs that fight cancer and AIDS. See Laurie McGinley, FDA to Quickly Clear Merck AIDS 
Drug, After Approving Abbott's Treatment, WALL ST. J. , Mar. 4, 1996, at B3 ( "On Friday, after 
late-night meetings Thursday between FDA and Abbott officials, the agency approved Norvir, 
known generically as ritonavir. That approval came just 72 days after Abbott filed its 
application-the fastest drug approval in the agency's modern history. And it came just one 
day after the advisory panel backed its approval."); The FDA and Shannon McDermott, BOSTON 
GLOBE, Apr. 15, 1996, at 10 [hereinafter McDermott]. It is important to note, however, that 
biotechnology encompasses a multitude of products and consumer groups do not support 
accessibility to all of them. Some well organized consumer advocacy groups presently oppose 
the "premature" commercialization of predictive genetic testing services. For example: 
The National Breast Cancer Coalition . . .  a patients' rights group, opposes open 
marketing of a test for the so-called breast cancer gene, BRCAl. At the risk of sounding 
as paternalistic as the doctors they often fight against, members said the test's generally 
ambiguous results may trigger unnecessary panic in many women while reassuring others 
who should remain vigilant. 
Rick Weiss, Tests' Availability Tangles Ethical and Genetic Codes, WASH. POST, May 26, 1996, 
at Al. 
81 The four primary forces driving expansion of the commercialization and availability of 
predictive genetic testing are: (1) the reward structure ofscience, which encourages immediate 
reporting of findings; (2) public demand for progress in battling disease; (3) biotechnology 
companies' objective of developing large markets, which are a pre-requisite to profits; and (4) 
media coverage of genetic discoveries. See TASK FORCE, supra note 8, at 4. 
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fundamental reform, 82 better organization and maturation 
(including more :financial resources) of the biotechnology industry,83 
vested pharmaceutical interest in the industry, 84 and the involve­
ment of the leadership of the scientific community (including the 
nation's major non-profit research institutions) in the biotech 
industry. 85 
It is more than mere coincidence, however, that the FDA's 
responsiveness has paralleled the establishment and progress of the 
EMEA. 86 The EMEA, not the FDA, now has authority over the 
82 The most dramatic features of the proposed FDA reform legislation are privatization of 
the review process (using private companies to help review clinical data) and a six-month (180-
day) time limit on the review of all drugs by 199S-a dramatic reduction compared to the 
current average of twelve months. See S. 1477, 104th Cong. (1996) (FDA Reform Markup 
introduced by Sen. Nancy Kassebaum); see also Malinowski & O'Rourke, supra note 1, at 210-
17; Pear, supra note 18, at A15; Ronald Rosenberg, Biotech Group Hits Kennedy's FDA Stance, 
BOSTON GLOBE, Apr. 26, 1996, at 90 [hereinafter Kennedy's FDA Stance] ("Citing scientific 
advances over the past 50 years, the biotech industry wants to abolish the two-track approval 
process for biology-based drugs. That process now requires separate approvals for a biological 
drug, its manufacturing process and for every lot or batch produced."). Other proposed reforms 
include: (1)  mandatory review, in four months as opposed to the present six, of all 
"breakthrough" drugs for fatal or incurable diseases; (2) requiring the FDA to distribute its 
work to private companies if it does not meet the proposed review deadlines by 1998; and (3) 
allowing companies, if the FDA fails to meet its deadline, to petition for automatic approval 
for sale in the U.S. of any therapy that is approved in certain foreign countries. If within 
thirty days the FDA finds the treatment "unsafe or unproven," it may ban the sale of the drug 
in the U.S. See Lauran Neergaard, Speed-up in Drug Approval Could Endanger Public, FDA 
Chief Warns, COM. APPEAL (Memphis), Feb. 22, 1996, at SB [hereinafter Speed-up]. The public 
pressures bearing upon the FDA also have been profound. See, e.g. , McDermott, supra note 
80, at 10 ("Janet McDermott[, who was brought to Washington by a pharmaceutical trade 
group,] is waging a valiant struggle to get medication that will prevent the seizures suffered 
by her daughter Shannon. But Shannon's plight should not encourage support for a bill in . 
Congress that would force the Food and Drug Administration to speed up the approval process 
for new drugs."). Appreciating the power of teamwork, drug companies have joined forces with 
patients in the fight to accelerate approval times. See Pear, supra note 18, at A15 ("Drug 
companies contribute substantial sums of money to patient-advocacy groups, but those groups 
insist that they are not unduly influenced by the money."). 
83 See EUROPOEAN BIOTECH 96, supra note 2, at 43 (pointing to the relatively mature U.S. 
biotech industry as a model for European companies); Malinowski & O'Rourke, supra note 1, 
at 169-70 (stating that the U.S. biotech industry has made great strides in the last five years 
in terms of revenue earned). 
a. See supra notes 48, 54 and accompanying text (mentioning the importance of alliances 
with the pharmaceutical industry). 85 See generally Malinowski & O'Rourke, supra note 1, at 180-84 (pointing to beneficial 
alliances with academia and research institutions). 86 Prior to the EMEA, three national agencies-those of the U.S., Britain, and France-set 
baseline standards for the world. See Reguly, supra note 51 (contrasting the EMEA's 
procedures with those of the FDA and suggesting that there is competition bet":'een t�e �wo 
to make fast approvals). Commissioner Kessler's statement that the FDA is reviewing 
biologics as fast, if not faster, than its national European counterparts evidences a reco�tion 
of this increased competition. See Ronald Rosenberg, KeSBler Defends FDA. Says US Quicker 
1996] Globalization of Biotechnology 137 
world's largest unified pharmaceutical market.87 The U.K., France, 
Germany, and Italy "account for nearly seventy-five percent of 
pharmaceutical consumption in the EU and thirty-five percent of 
global consumption. "88 
The EMEA, headquartered in London, was established in 1993 to 
implement legislation known as the Future System for the market 
authorization of medicinal products for both animal and human 
use.89 There now are three procedures for market authorization 
within the E.U.: ( 1) a centralized procedure for access to the E.U. 
market; (2) a decentralized procedure for access to the E . U. market; 
and (3) national authorization for access to a country's domestic 
market.90 
(1) Centralized Procedure . The centralized procedure applies 
to all biotechnology products. 91 The procedure also may be 
available upon request for other innovative products and new 
chemical entities.92 Authorization, which is valid for 
marketing in all E.U. Member States, is granted based upon 
at Getting Drugs Ok'd, BOSTON GLOBE, Mar. 12, 1996, at 34 [hereinafter Kessler Defends FDA] 
(noting that in a five year period, thirty drugs were approved in the U.S. and twenty-eight in 
the U.K.). However, some experts suggest that 
the time for NDA approval is decreasing only because the FDA is asking for substantially 
more clinical data before it starts its NDA review 'clock.' The Center for the Study of 
Drug Development at Tufts University found that from 1990 to 1992, although median 
review time for 'important' new drugs was 20 months instead of 31 for other products, 
development times for the former group were three years longer. 
FDA Reform, supra note 5 1 ,  at 2015 (internal citations omitted); see also infra note 1 16 and 
accompanying text (discussing Commissioner Kessler's concern over proposed FDA reforms). 
87 See Bent & Booth, supra note 18, at C3 ("[N)ow the . . .  [EMEAJ administers a unified 
regulatory system for a substantially larger population than that of the United States, and 
may displace the FDA as the regulatory standard-bearer."). 
88 Cavalier, supra note 51, at 459. 
89 See Background Report, supra note 51. The EMEA is responsible for "providing Member 
States and the Community institutions with the best possible advice on any question relating 
to the quality, safety and efficacy of medicinal products for human or veterinary use." Id. 
Other responsibilities include "improving cooperation between the Member States, the 
Community institutions, international organi[z]ations and third countries on the safety of 
medicines." Id. The EMEA is financed by the Community and through fees paid by the 
pharmaceutical industry. See id. For discussion of the EMEA, its procedures, and its impact 
on the industry, see generally EUROPEAN BIOTECH 96, supra note 2, at 1 9-20 (discussing 
approval times and the effects of the EMEA on the confidence of investors); EUROPEAN BIOTECH 
95, supra note 26, at 16 (explaining staffing, start-up costs, and future approval procedures). 90 These procedures, summarized below, are described in Background Report, supra note 51; 
EMEA, supra note 51; and Cavalier, supra note 51, at 463-64. See also FDA Reform, supra 
note 51, at 2012-15, 2019-21; Eyckmans, su:pra note 29 at 32. � ' See Background Report, supra note 51. 
92 See id. 
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a single evaluation by one o� the EM��s scientific 
panels-the Committee for Propn�tary Me�c1.
nal Products 
(CPMP) or the Committee for Vetennary Medicmal Products 
(CVMP).93 An opinion must be granted within 2 10 days 
from the filing of the application, and a final decision on the 
application must be granted in less than 300 days.94 • Any 
applicant receiving a negative opinion has an opporturuty to 
appeal.95 When a positive opinion is rendered, E.U. Member 
States are obligated to recognize the new drug for sale in 
their borders or file a formal objection with the European 
Commission.96 The duration of authorization is five years, 
with the ability to renew exclusive marketing rights for 
another five years if safe use can be shown.97 Upon ap­
proval by the EMEA, a drug "cannot be rejected by the 
national regulators."98 
(2) Decentralized Procedure. Until January 1998, applicants 
also may opt for the traditional multi-state, parallel ap­
plication process for conventional drugs, whereby applications 
are filed and reviewed by different Member States at the 
same time. 99 Authorization granted by any one Member 
State-which should be decided within a period of 300 days, 
consisting of a 210-day review period and a ninety day 
translation and certification period-may be extended to other 
Member States upon application for recognition.100 A Mem­
ber State receiving such an application may defer action 
pending the action of a Sister State, and then "base its 
assessment on that of the other State. "101 As with the 
centralized procedure, unfavorable decisions may be ap­
pealed.102 
98 See id. 
"' See id. 
86 See id. 
1111 See id. 
� See id. 
1111 Reguly, supra note 51. 
" See ll B loo genera Y ackground Report supra note 51· EME'A See id. ' • �. supra note 51.  101 S E ee MEA, supra note 51 102 See id. 
· 
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(3) National authorization. The individual Member State 
application procedure remains an option. Pursuant to this 
procedure, a company may seek authorization for a drug from 
any individual Member State that is limited to the State's 
national market. 103 
139 
Prior to the establishment of the EMEA, European drug firms 
were falling behind those of the U.S. and Japan.104 The purpose 
behind the EMEA is to "exploit product licensing expertise available 
in the European Community. "105 In particular, the E. U. intends to 
create an efficient application process to "enhance the value of 
pharmaceutical advances by reducing the time necessary for 
technology transfer and, thus, [make] products available to the 
market more quickly."106 The cost of E.U.-wide approval under the 
EMEA is expected to be just sixty percent of the cost of obtaining 
authorization from the fifteen individual Member States. 107 During 
its first thirteen months of operation, the EMEA, which has the 
capacity to approve some forty therapeutics per year, fully approved 
seven drugs, all biotech drugs developed by U.S. companies, and 
partially approved many more. 108 In addition to the benefits of 
103 See id. 
104 See A Drug Tsar is Born, THE ECONOMIST, May 7, 1994, at 74. In addition to delays 
accompanying the need to seek approval from individual states, the pharmaceutical and 
biotechnology sectors of the E.U. industry also have been held back by some national hurdles 
that remain, such as price controls and advertising regulations. See Fast Relief, supra note 18, 
at 7 ("Except in the U.K and Germany, companies can launch the [EMEA-approved] product 
only after elaborate bargaining with national authorities over pricing and reimbursement 
levels."); see also Cavalier, supra note 51, at 459 ("Pricing is well within the jurisdiction of the 
individual member country, and a unified pricing system is not likely in the near future due 
to 'differing socio-economic factors and reimbursement systems.'"). But see Eyckmans, supra 
note 29, at 32 (applauding a series ofE.U. directives which are slowly creating a single market 
for pharmaceutical products); infra notes 208-09 and accompanying text (discussing how rules 
were adopted by the European Commission in 1992 to standardize labeling and harmonize 
requirements for patient information). 
105 EMEA, supra note 51. 
106 Id. ("Bypassing the national regulators means that drugs can reach more [sic] more 
markets more quickly. Today, the top companies strive to launch drugs with an annual sales 
potential of Pounds 500 million. Saving months of tortuous regulatory proceedings could 
generate hundreds of millions a year in extra sales."). See Reguly, supra note 51 (explaining 
that the EMEA will improve the efficiency of the approval process by bypassing national 
regulators to allow for Europe-wide clearance). 
107 See US GAO Views Euro Drug Approval Times, MARKETLETI'ER, Apr. 22, 1996, available 
in 1996 WL 9648419. 
108 See Reguly, supra note 51. The first drug approved by the EMEA was Gonal-F, an 
infertility drug manufactured by Britain's own Serono Laboratories, and the most recent was 
Novo-7, a therapeutic that reduces bleeding. See id. (stating that EMEA's start was slowed 
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accelerated review, companies may ask the EMEA for scientific 
advice long before filing applications, and the EMEA has been 
increasing this advisory function since its establishment. 109 
There are strong similarities between the Future System 
implemented through the EMEA and proposed FDA reforms. As 
stated above, EMEA application review time is limited to 210 days, 
whereas the Kassebaum. proposal includes a 180-day time limit. 110 
The EMEA is a lean agency with a London staff of merely 100 that 
contracts out essential operations to national regulatory agencies 
across Europe.111 Similarly, the movement to reform the FDA 
includes strong support to privatize the review process through 
contracts with outside laboratories. 112 Even the FDA has proposed 
outside review for low-risk medical devices. 113 In addition, the 
EMEA and FDA reform movements each face domestic resis­
tance. 114 In the U.S., resistance over the speed and extent of 
reform comes from the agency itself and its supporters. 115 Accord­
ing to Commissioner Kessler116 and Senator Kennedy,117 the FDA 
by the fact that "its use is optional except for new biotech drugs such as vaccines"). The CPMP 
approved fifteen drugs during the EMEA's first year of operation (all developed by U.S. 
companies), in comparison with twenty-eight new drugs cleared by its FDA counterpart. See 
id; see also Success, supra note 51 (stating that, by the end of 1995, the EMEA had adopted 
8 positive opinions on applications, leading to three authorizations before the end of the year). 
109 See Success, supra note 51. 
. 
110 See S. 1477, 104th Cong. ( 1996). 
m See EUROPEAN BIOTECH 95, supra note 26, at 16; Fast Relief, supra note 18, at 1; Reguly, 
supra note 51 ("Operationally, the EMEA does not work like the national regulators or the 
FDA. It essentially acts as a contractor, farming out most of the scientific review work to 
experts approved by the EU states."). 
112 See supra note 18 (regarding the FDA reform movement). 
113 See i.d. 
114 See Reguly, supra note 51; Kennedy's FDA Stance, supra note 82, at 90 (remarks of 
Senator Kennedy). 
116 See Kennedy's FDA Stance, supra note 82, at 90. 
116 See supra note 86. FDA Commissioner Kessler warned Congress that the proposed 
reforms could endanger the health of Americans. See Legislation Puts Public Health at Risk, 
FDA Chief Tells Panel, BOSTON GLOBE, May 2, 1996, at 9 [hereinafter Legislation]; Speed-up, 
supra note 82, at SB. Commissioner Kessler has challenged the proposed FDA reforms by 
asserting that: (1) the FDA has accelerated its review process, as made evident by the recent 
approval of AIDS drugs. See Kessler Defends FDA. supra note 86, at 34; (2) the U.S. has 
reviewed and introduced major biotechnology drugs at least as quickly as its European counter· 
parts. Id.; and (3) the FDA has often discovered problems that were missed by regulators 
overseas. See Speed-up, supra note 82, at 8B. As examples of the latter, Kessler cited the 
FDA's rejection of the blood pressure medicine dilevodol in 1989 because it caused fatal liver 
disease, which prompted Britain and other countries already selling the drug to ban it. See 
id.; see also Legislation, supra, at 9 ("Americans would be at risk of getting infected blood 
transfusions and being poisoned by the food supply under pending legislation to revamp the 
Food and.Drug Administration, the agency's chief said yesterday."). Dr. Kessler's conclusions 
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may overlook the following: 
0 The EMEA was established in 1993 to eliminate acknowledged inefficiencies. 
0 Although the biotech industry is undergoing globalization, the majority of the biotech 
industry is located within the borders of the U.S. See Malinowski & O'Rourke, supra note 
1, at 169; Reguly, supra note 51. In terms of the first generation of biotechnology 
products now reaching consumers, the industry is as American in origin as the automobile 
industry and Microsoft. Its presence has been visible in the U.S. for years, and NIH has 
financed a vast amount of basic biotech research. See Malinowski & O'Rourke, supra note 
1, at 203-04. The importance Dr. Kessler places upon collaboration and interaction 
between drug reviewers and industry underscores the fact that the FDA has had an 
incredible home-court advantage over its foreign counterparts. See Kessler Defends FDA, 
supra note 86, at 34. Even if Dr. Kessler's data is correct, and safe, efficacious biotech 
products now are reaching consumers in the U.S. at roughly the same time that those 
products are reaching consumers in the U.K., such an outcome certainly is no basis for 
declaring success. One can only wonder how Dr. Kessler's comparative data would be 
affected by granting the drug reviewers in the U.K. the advantage held by his staff. Also, 
as the EMEA hones its operation, biotech products may reach E.U. consumers much more 
quickly than their U.S. counterparts, regardless of where they are developed and the 
trials are conducted. 
0 Before post-HGP biotech products reached the FDA, it was expected that they would 
move through the approval process much more quickly than their chemical compound 
predecessors due to the fact that they are composed of natural molecules. Instead, there 
was added delay-due in part to archaic regulations for biologics and the novelty of the 
new products which caused a lot of second guessing by regulators. See Malinowski & 
O'Rourke, supra note 1, at 205-13. Along the same lines, simply passing a generation of 
novel biotech products through the FDA would result in elimination of the novelty factor 
and more rapid review of the biotech products that follow. In other words, even if nothing 
was done to remove FDA inefficiencies and excessive burdens, the time required for FDA 
review of biotech products should be decreasing. 
0 Although the FDA has made some improvements and is in the process of making more 
to hasten its review of needed products without abandoning prudence, the recent 
expedited review of AIDS drugs is not representative. See Kessler Defends FDA, supra 
note 86, at 34. These successes likely are more attributable to the political voice of AIDS 
activists and the threat of proposed Congressional reform than meaningful self­
improvements by the FDA. See Malinowski & O'Rourke, supra note 1, at 210-13; McDer­
mott, supra note 80, at 10 (noting that pressures placed on Congress by AIDS and cancer 
activists led to faster approvals for some drugs). One cannot conclude that the pace of 
review achieved with these AIDS drugs will be sustained for the tremendous pipeline of 
important biotech drugs that feeds into the FDA. Furthermore, Dr. Kessler conveniently 
neglected to address the costs of this accelerated review. 
117 See 142 Cong. Rec. S3203-01 (daily ed. Mar. 29, 1996) (statements of Sen. Edward 
Kennedy regarding the FDA Reform Markup); Kennedy's FDA Stance, supra note 82, at 90. 
In the words of Senator Kennedy: 
Most recently, we reduced the delays in approving prescription drugs With user fees. 
As a result, we are now approving drugs faster than the United Kingdom. We have fixed 
the drug lag. In fact, the United States approves more important new drugs faster than 
any other country in the world . 
. · · :  The [proposed] legislation says you have to examine all of them, all of the drugs 
within 
_
the � months . . . .  So now instead of bringing focus and attention of the gifted and 
able scientists out at FDA on those drugs that could be breakthrough drugs in cancer in 
AIDS, in hepatitis, in all kinds of diseases, we are going to divert their attention' to 
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will not be able to meet the proposed 180-day requirement and 
maintain quality assurance. Resistance to the EMEA is likely to 
come from Member State national regulators, for the EME.Ns success 
is necessarily at their expense.118 
Fundamental reforms, such as the establishment of the EMEA and 
enactment of some of the significant proposed FDA reforms, could 
mean dramatic improvements to human health and the facilitation 
of greater economic prosperity. As a result, public and political 
pressures are on the FDA and EMEA to maximize review and 
accelerate approval of biotechnology applications and other in­
novative technologies without sacrificing quality assurance. Despite 
the loftiness of this objective, the FDA and EMEA are both striving 
to obtain it-each with an eye on the other. 119 
B. The Shared Health Care Finance Challenge 
No one disputes that biotechnology can introduce diagnostic and 
treatment capabilities that will improve public health by adding 
quality and longevity to countless lives. 120 Biotechnology advances 
also may realize some immediate, short-term savings in health care 
costs by, among other things, improving patient diagnosis and 
identifying how well patients will respond to treatments.121 
Nevertheless, the paradox of medical technology is that, the more 
effectively advances in health care technology benefit public health, 
the more medical technology raises health care costs over time.122 
looking after the "me-too" drugs that can make extra bucks for the pharmaceutical 
companies. 
142 Cong. Rec. 83203-01. 118 See Reguly, supra note 51. 119 See supra notes 51, 78-79 and accompanying text. 120 See BOSTON CONSULTING GROUP INC., THE CoNTRIBUTION OF PHARMACEUTICAL 
COMPANIES: WHAT'S AT STAKE FOR AMERICA 63, 63-65 (Sept. 1993) [hereinafter BOSTON 
CONSULTING GROUP] (detailing the development of drugs aimed at treating the ailments that 
plague society). 121 "[T]he study of genetic variation will enable the identification of patient sub-populations 
that may respond particularly well or poorly to currently-marketed drugs." GENOMICS, supra 
note 3, at 5. "Drugs developed using genomics technology can be expected to offer advantages 
in specificity that will result in therapeutics with fewer side effects." Id. at 9. "The ability to 
eliminate ineffective therapies due to individual therapeutic response will be another way in 
which genomics will contribute to the reduction in health care costs . . . . Genomic diagnosis 
will provide physicians with a sound basis upon which to prescribe appropriate therapies." Id. 
at 16. 
122 See BOSTON CONSULTING GROUP, supra note 120, at 3, 49 (discussing cures for disease, 
which have increased life expectancies, and new technology as potential causes for increases 
in health care costs); New Era, supra note 9, at 341-47; EU: Pluses and Minuses of 
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The reasons are multifold: 123 
Susceptibility to more complex diseases. During this century, 
medical technology has helped to raise life expectancy at birth 
from fifty-four years in 1920 to seventy-five years in the early 
1990s; the death rate from disease has fallen by more than 
one-third during that time.124 "[L]ongevity is the equivalent 
of susceptibility to new, more complex diseases that are more 
difficult to treat and require specialized, technology-intensive 
care."125 The most pressing diseases currently challenging 
medical science are no less significant, threatening, or 
complex than heart disease, cancer, and AIDS. "Accordingly, 
effective medical technology increases the need for more 
advances and scientific research and development (R&D}, and 
also increases consumption of technology-intensive, . l" d d . t t t "126 specia ize an expensive rea men s. 
143 
Increases to the ranks of the biggest consumers. Medical 
technology increases both "the ranks of the elderly, the 
Pharmacoeconomics, MARKETLETTER, July 17, 1995, available in 1995 WL 2153623 ("[A]nalyses 
[sic] of the factors raising health spending always reveal that innovation is the single most 
important driving factor."). The Boston Consulting Group, based upon an empirical study 
published in 1993, concluded that 
The $461.2 billion increase in health care costs between 1963 and 1987 has several root 
causes . . . . Technological innovation, increased use of medical services, and real 
increases in medical prices together were responsible for more than 50 percent of the 
increase. Additional births and immigration accounted for 6 percent, and the increase in 
the size of the population due to increased life expectancy contributed 2 percent. Of the 
remainder, 19 percent was general inflation and 21 percent was the increased cost per 
capita of treating the elderly, beyond the rate of increase experienced for the rest of the 
population. 
BOSTON CONSULTING GROUP, supra note 120, at 48. 
123 See New Era, supra note 9, at 341-47 (discussing these reasons at length). 
124 See BOSTON CONSULTING GROUP, supra note 120, at 3 .  Pharmaceuticals have provided 
the treatment or means of prevention for six of the top eight categories of killer diseases of the 
1920s: diphtheria; influenza; measles; pneumonia; syphilis; tuberculosis; and whooping cough. 
See id. at 4. 
125 New Era, supra note 9, at 341-42 (citation omitted). "Thus, paradoxically, even if another 
'penicillin' was discovered that inexpensively cured the prevalent diseases of today, the 
population would eventually age to the point where some new set of diseases would be killing 
(much older') people at essentially the same rate." BOSTON CONSULTING GROUP, supra note 
120, at 12. Specialization has the potential to increase the cost of care because the lack of 
substitutes and high demand for services allow specialists to set high prices. See New Era, 
supra note 9, at 342 n.77. 
126 11.T J.vew Era, supra note 9,  at 342. In 1993, "annual medical spending and indirect social 
costs for cardiovascular disease [reached approximately] $110 billion." BOSTON CONSULTING GROUP, supra note 120, at 46. 
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nation's biggest health care consumers," and the amount and 
complexity of the services available to them.127 
Increased services. "When medical technology is available, it 
seems inevitably to be used, even in the face of objective data 
that it is inappropriate."128 In fact, "[m]edical technology 
actually creates new treatable conditions. "129 
The field of biotechnology already is responsible for an entirely 
new generation of diagnostics and therapeutics now entering 
consumer markets. As evidenced by the burgeoning nature of 
biotechnology and globalization of the industry, 130 countless more 
127 New Era, supra note 9, at 342; see BOSTON CONSULTING GROUP, supra note 120, at 11 
("On average, the elderly consume four times as much medical care as do people under 65 
. . . .  "). "According to the Congressional Budget Office, 64. 7% of the growth in Medicare 
spending is attributable to increased services and use of technology, and Medicare consumed 
approximately 11.6% of all federal spending in 1995-meaning seventy-seven percent of the 
nation's health care bill for that year." New Era, supra note 9, at 342 (citation omitted). 
128 Henk A.M.J. ten Have, Medical Technology Assessment and Ethics: Am.bivalent Relatwns, 
HAsTINGS CENTER REP., Sept.-Oct. 1995, at 13, 16. 
129 New Ero, supra note 9, at 342. A prime example of this effect is the impact of medical 
technology on short stature and infertility. See id. 
Human growth hormone was developed initially to treat children whose bodies failed to 
produce it in standard amounts, a condition known as growth hormone deficiency (GHD). 
Now, recombinant DNA technology has made growth hormone much more available, and 
there is some evidence that the physical characteristic of short stature apart from GHD 
will become a treatable condition. 
Id. (citing Henk A.M.J. ten Have, supra note 128, at 16; Carol A. Tauer, Human Growth 
Hormone: A Case Study in Treatment Pri.orities, HAsTINGS CENTER REP., May-June 1995 
(Special Supp.), at 818; Gladys B. White, Human Growth Hormone: The Dilemma of Expanded 
Use in Children, 3 KENNEDY INST. ETHICS J. 401, 401-09 (1993) (emphasis added)). See Leona 
Cuttler et al., Short Stature and Growth Hormone Therapy: A Nati.anal Study of Physician 
Recommendatwn Patterns, 276 JAMA 531, 531 (1996) (reporting on study findings that many 
pediatric endocrinologists consider GH treatment appropriate for selected non-GHD children). 
"Four years of GH treatment at $20,000/year for the 37,000 children in the first height 
percentile at any given age would cost $3 billion a year." Carol A. Tauer, Human Growth 
Hormone: A Case Study in Treatment Priorities, HAsTINGS CENTER REP., May-June 1995 
(Special Supp.), at 818, 819. Similarly, infertility has become a treatable condition despite the 
fact that its success rate is approximately 25% for women age thirty-seven or older. See Gail 
Sheehy, Northwest Living: When Time Runs Out on Fertility, PORTLAND OREGONIAN, Oct. 22, 
1995, at L07, available in 1995 WL 9201540 (breaking success rates down by age groups). The 
success rate even has been reported to be as low as 10% to 18% at a cost of $7,800 to $ 15,000 
per attempt. See Lisa Benavides, Winchester Biotech Develops New Fertility Treatment, 
BOSTON Bus. J., Aug. 16, 1996, at 9, available in 1996 WL 8817873. Several states, including 
Arkansas, Hawaii, Illinois, Maryland, Massachusetts, and Rhode Island, require insurance 
companies to cover fertility treatments and other states are considering similar laws. See Earl 
Ubell, If You 're Trying to Have a Child . .  ., PARADE MAG., Oct. 6, 1995, at 12, 12. 
130 See generally supra Part II (discussing the growth of biotechnology in the U.S. and the 
U.K). 
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innovations will follow.131 Today "a critical mass of the HGP has 
been completed, which suggests that the pipeline of products is about 
to get much fuller. "132 Although "there will be some cost savings 
as researchers match diagnostic capabilities with therapeutic 
capabilities[,] . . .  the first generation of genetic technologies will 
inundate the health care system with new costs over the next several 
years."133 The DNA diagnostic market is expected to exceed one 
billion dollars by 1998, an amount which does not include the 
expense of genetic counseling.134 Many genetic therapeutics will 
be extraordinarily expensive due to their novelty and lack of market 
substitutes, both of which are reflected in the R&D costs of 
131 See New Era, supra note 9, at Part 11.B.3. "Genetic technologies are by no means a 
homogenous lot; they have varied medical and social effects, and are intended for diverse 
populations with distinct severity of illnesses, both actual and potential." Philip J. Boyle, 
Public Priorities for Genetic Services, HAsTINGS CENTER REP., May.June 1995 (Special Supp.), 
at Sl,  81. "[A] plethora of population screens, diagnostic tests, and therapies will be 
available-perhaps commonplace-in the next decade. Conservative estimates are that some 
50,000 gene markers will be developed as a result of molecular biology and translated into 
easy-to-employ biochemical assays, genetic tests, new drugs, and genetic therapies." Philip J. 
Boyle, Shaping Priorities in Genetic Medicine, HAsTINGS CENTER REP., May.June 1995 (Special 
Supp.), at S2, S2 [hereinafter Shaping Priorities]. The future of biotechnology is brightened 
by strong bipartisan support in Congress for biomedical research. See John K. Iglehart, 
Politics and Public Health, 334 NEW ENG. J. MED. 203, 203-07 (1996). See generally 
Malinowski & O'Rourke, supra note 1, at Part I.A. (discussing the growth of the genotech 
industry and the influences of government upon that growth); LEE & BURRILL, supra note 2 
(discussing the future of biotechnology and the growth of new diagnostic products and drugs). 
132 New Era, supra note 9, at 343. See Detailed Human Physical Map Published by 
Whitehead-MIT: S TS-Based Map Represents Halfway Point to 100-kb Human Genome Project 
Goal, HUM. GENOME NEWS, Jan.-Mar. 1996, at 5 ("The new map, which contains more than 
15,000 STS DNA markers spaced an average of 199 kb apart, covers almost 95% of the entire 
genome . . . .  Although originally slated for 1998, map completion by Whitehead-MIT and other 
groups is expected by the end of this year."). 
133 New Era, supra note 9, at 344 (citation omitted). "Gene therapy is creating the potential 
for dramatic cost reduction by restoring normal function in congenital diseases like cystic 
fibrosis and [adenosine deaminase] deficiency." Elizabeth 0. Teisberg et al., Making 
Competition in Health Care Work , HARV. Bus. REV., July-Aug. 1994, at 131, 139. According 
to one study, 
biomedical advances ,  as well as changes in lifestyles, are projected to avoid billions of 
dollars in total health care costs by the year 2015, including $76 billion of costs avoided 
for Alzheimer's disease and $12 billion for arthritis . . . .  When economic costs are factored 
in-lost or inefficient work days-the costs avoided are even greater. 
New Era, supra note 9, at 344 n.96 (citing BOSTON CONSULTING GROUP, THE CHANGING 
ENVIRONMENT FOR U.S. PHARMACEUTICALS 52 (Apr. 1993)). But see Mark J. Hanson, The 
Seductive Sirens of Medical Progress: The Case ofXenotransplantation, HAsTINGS CENTER REP., 
Sept.-Oct. 1995, at 5, 6 ("The general irony of the cost-effectiveness argument is that because 
there will likely always be another cause of morbidity or mortality following the one medicine 
has prevented, there will always be a new investment opportunity for medicine."). 
134 See Paul H .  Silverman, Commerce and Genetic Diagnostics, HAsTINGS CENTER REP., May­
June 1995 (Special Supp.), at S15, S16. 
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developing them. 135 The first products are likely to generate high 
demand because biotech companies, most being without product 
lines, have focused their R&D efforts on technologies that will draw 
the broadest possible consumer markets.136 Therefore, "[ w ]hen 
they reach market, the first generation of commercialized genetic 
technologies will hit health care insurers hard, especially if, as 
expected, many reach commerce en masse and over a brief period of 
time."137 
The challenge of financing biotechnology will have a significant 
impact on the health care systems of both the U.S. and the U.K. 
Escalating competition for limited resources will increase the 
pressure on health care policy-makers in both the U.S. and the U.K. 
to choose which research projects to support and what effective 
health care technologies to make available to patients. In other 
words, there will be trade-offs. Moreover, as shown by the 
cooperative nature of the industry in both countries, 138 the U.S. 
and the U.K. have already realized limitations on public funding of 
medical science R&D and an increase in private funding. 139 
136 "A case in point is Genzyme's Ceredasae/Cerezyme, a treatment for Type 1 Gaucher's 
disease. The treatment costs $150,000 a year initially, followed by a maintenance program of 
monthly infusions for the rest of the patient's life at a cost of approximately $60,000 per year." 
New Era, supra note 9, at 344 n.99 (citing Ronald Rosenberg, Genzyme's Plans to Beat Obsoles­
cence, BOSTON GLOBE, Jan. 8, 1995, at 60). See NIH Technology Assessment Panel, Gaucher 
Disease: Current Issues in Diagnosis and Treatment, 275 JAMA 548, 552 (1996) (concluding 
that treatment is limited by the high cost of the agent's initial availability in the marketplace). 136 See New Era, supra note 9, at 344. 137 Id. See Malinowski & O'Rourke, supra note 1, at 177-78 (noting that "an entire 
generation of novel drugs is already visible . . .  [because] the underlying science has proceeded 
more quickly than expected"). 138 See supra Part II. 139 See supra notes 24, 28 and accompanying text (discussing the privatization trend in the 
U.S. and the significance of the Wellcome Trust in the U.K.). In the U.K., "while the 
government's contribution to industrial research spending has declined from 30 per cent in 
1967 to 1 7  per cent in 1990, industry's own share of the cost has remained at about 68 per 
cent." John Maddox, British Report Real Decline in Spending on Research, 358 NATURE 359, 
359 (1992). Recent cuts in medical R&D have raised an outcry from university officials. See 
Wellcome Cash, supra note 28, at 58 ("The Wellcome Trust is now roughly the same size as the 
Medical Research Council, a body that allocates British government funds to biomedical 
research."); Fran Abrams, Training Cuts Put Patients in Danger, INDEPENDENT (London), Apr. 
27, 1996, at 5, available in 1996 WL 9923611 (stating that "[u]niversity funding cuts, 
[including huge cuts to major research projects], have plunged medical schools into crisis"); 
Chris Mihill, Cuts in Funding 'May Cost Lives, ' GUARDIAN (London), Apr. 27, 1996, at 008, 
available in 1996 WL 4021902 (reporting that university officials warn that "new treatments 
and drugs [will] go undiscovered because of a lack of time and research facilities"); Celia Hall, 
Medical School Cuts 'Will Put Lives in Danger, ' DAILY TELEGRAPH (London), Apr. 27, 1996, at 
10 available in 1996 WL 3945408 (reporting a loss of 107 million pounds "in real terms, 
co:nbined with an overall grant cut of five per cent"). 
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The resulting introduction of intense entrepreneurialism and 
extensive industry interests and capital in the medical science 
community, set in the context of global competition, also appears to 
be giving rise to more incidents of fraud and abuse of patient 
trust.140 At the same time, corporate discretion is increasing in the 
U.S. as biotech companies are performing research-stage 
presymptomatic genetic testing services in-house for consumers 
through primary care physicians.141 One fear is that biotechnology 
companies increasingly will satisfy the technical laboratory re­
quirements under the Clinical Laboratory Improvement Amendments 
of 1988 (CLIA)142 by assembling their own Institutional Review 
Boards (IRBs)143 staffed with highly-paid consultants. 144 
140 See Nicholas Timmins, Call for Agency to Stop Medical Research Fraud, INDEPENDENT 
(London), Mar. 29, 1996, at 6, available in 1996 WL 4065890 (providing several examples, 
including the forging of patient consent forms for drug company sponsored trials by Dr. 
Geoffrey Fairhurst, a former advisor to the British government and then vice-chairman of the 
General Medical Council's ethics committee in England). In March 1996, "[i]n a unique 
collaboration, the Lancet and the British Medical Journal produced separate leading articles 
demanding action as a new book detailed more than 70 proven or suspected cases of scientific 
dishonesty and fraud worldwide." Id. See Chris Mihill, Doctors Urge Action to Curb Research 
Cheats, GUARDIAN (London), Mar. 29, 1996, at 008, available in 1996 WL 4017315 (stating that 
"[o]ne in 250 scientific studies may be fraudulent"). 
141 These tests are commonly known as "home brews." See Richard S. Schifreen & Cynthia 
Louth, Industry View on the Regulation of Ancillary Reagents, 5 1  FOOD & DRUG L.J. 155, 158-
59 (1996). 142 CLIA was implemented to protect human subjects. See 42 C.F.R. § 493. 1 ( 1995) 
(requiring certification before laboratories perform tests on humans); Malinowski & Blatt, 
supra note 8 (manuscript at 18-19) (arguing that "there can be no reliance on state regulation 
to monitor . . .  the quality of genetic testing services for, there too, 'the field of laboratory 
licensure and monitoring remains in a state of flux'") (citing ROBIN J.R. BLATT, CONCEIVING 
THE FuTuRE: THE X's AND Y's OF GENETIC TESTING IN PREGNANCY (forthcoming 1997 
Greenwood Press)). Private laboratories performing genetic testing services are also essentially 
immune to federal laboratory quality assurances imposed by the Health Care Finance 
Administration (HCFA) through CLIA, for it is easy for them to satisfy CLIA requirements. 
Under CLIA, "a laboratory must demonstrate analytical validity of its tests and their 
components," but there is no clinical validity requirement. TASK FORCE, supra note 8, at 14-15 
(emphasis added). In other words, the CLIA validity requirement is satisfied when a test to 
determine the presence of a specific genetic alteration does so accurately even though the test 
may offer no clinical predictability (the influence of the genetic alteration tested for on the 
health of individual subjects has not been established with clinical reliability). See Shaping 
Priorities, supra note 131,  at 87 (discussing the failure of CLIA to address the impact of genetic 
tests on patient care). 143 There is no express requirement that the genetic alteration tested for has any bearing 
on the subject's health. The only CLIA patient care safeguard touching upon clinical quality 
is the requirement that the proposed clinical protocol receive Institutional Review Board (IRB) 
approval when an investigatory test enters the human trial phase. See Stephenson, supra note 
8� at �662. Academic laboratories are required to report to their standing IRB, but "[t]he situation with respect to IRBs is murkier for biotechnology companies and commercial 
laboratories. They also may consult an IRB of an academic institution with whom they have 
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The economic reality of health care coverage in both the U.S. and 
the U.K. dictates that many patients who probably would b�ne�t 
from a given medical science capability will not be able to receive it. 
In the U.S., such choices necessitate aban�onmen� of a no-concer�� 
for-costs mentality that has governed medical ethics for decades.  
This jolting change, imposed through the wildfire spread of managed 
care and the introduction of harsh :financial incentives on providers, 
threatens the physician-patient relationship.146 In contrast, 
rationing has been internalized for physicians practicing under the 
nationalized U.K. system, and the U.K.'s public has become used to 
(if not accepting oO the resource limitations of health care. 147 
In the long-term, however, the widespread commercialization of 
biotechnology advances could pose a greater challenge to the U.K for 
several reasons. First, in the U.K. health care system, there is 
relatively less waste available to be tapped to finance more 
ties, or they may form their own !RB-a practice that has the potential for a conflict of 
interest." Id. See ABRAHAM, supra note 49, at 22-25 (exploring the capture theory in the 
context of IRBs, suggesting that those from the medical profession who serve on IRBs reap 
tremendous financial rewards and may receive R&D funding from the manufacturer of the 
products they are reviewing); TASK FORCE, supra note 8, at 11 ("The Task Force recognizes that 
IRBs differ widely in their approach to clinical protocols and in their policies regarding what 
constitutes research in their purview."). 
144 See Joseph Palca, Institutional Review Boards: A Net Too Thin, HAsTINGS CENTER REP.,  
May 15, 1996, at 4 (discussing the flawed IRB system and the initiative to introduce legislation 
to establish a national requirement for IRB approval for any human research). 
146 See New Era, supra note 9, at 359 ("The reality of modern medicine, meaning the 
medicine of today and tomorrow, is that costs do matter."). In accordance with the professional 
dominance and bioethics eras in medical ethics, medical schools have trained physicians not 
to consider costs. There is no cost-effectiveness requirement for FDA approval, and "[o]nly in 
the past few years have care managers begun convincing technology suppliers regularly to 
incorporate cost-reduction objectives in their decision-making." BOSTON CONSULTING GROUP, 
supra note 120, at 67. 
146 See David Orentlicher, Health Care Reform and the Patient-Physician Relationship, 5 
HEALTH MATRIX 141, 142 (1995) (arguing that health care reform may cause "patients' primary 
relationships [to] be with their health care insurers rather than their physicians . . .  [and] 
would accentuate the conflict between patient needs and the physician's personal fmancial 
interests"). 
147 In the U.K, "'despite the severity of financial constraints-the British system spends 
only
_ 
�ne-third per capita of what [the U.S.] does-physicians seldom consciously engage in explmt cost-benefit calculations.' Moreover, 'British doctors still profess just as strong an ethic 
of absolute quali�."' New Era, supra note 9, at 340 (quoting Mark A. Hall, Rationing Health Ca
_
re at the Bedside, 69 N.Y.�. L. �- 693, 713, 738 (1994)). "Critics of the British system point out, however, that the mcentive to conserve imbedded in British doctors has limited care."
, 
Id. at 340 n.68 (citing Glen C. Griffin, MD/ DO Jobs and Incomes May Shrink but There s Good News: CUA Office Lab Regs May Go!, 97 POSTGRADUATE MED May 1 1995 at 13). ., , ' 
1996] Globalization of Biotechnology 149 
capabilities.148 Second, in comparison with U.S. providers, U.K 
providers prescribe more drugs and perform fewer surgeries.149 
Third, "[i]n the United Kingdom, nearly all drugs are reimbursed by 
the government's National Health Service (NHS), and an estimated 
eighty-five percent of prescriptions are dispensed free of charge."150 
In contrast, the U.S. government funds only twelve percent of . t' 151 prescnp ions. 
In sum, health care technology in the U.S. "is becoming an enemy 
to public health because it has not been made part of a deliberate 
strategy for managing care. "152 Advances in molecular biology and 
genetic medicine are changing the emphasis in advanced health care 
technology from machinery and complex surgical procedures to 
diagnostics and therapeutics. 153 The U.K. also faces this problem 
due to its pattern of heavy drug consumption, its practice of 
reimbursement for the costs of prescriptions, and the transaction 
costs (including industry disincentives) associated with negotiation 
148 The British practice of rationing health care, in comparison to the American system, 
results in a difference in the rate of provision of certain treatments in the two countries. Each 
year in the U.K., 9000 people are denied renal dialysis, between 10,000 and 15,000 are denied 
cancer chemotherapy, between 4000 and 17,000 are denied coronary artery surgery, and 7000 
are denied hip replacement surgery. See JANE M. ORIENT, YOUR DOCTOR IS NOT IN: HEALTHY 
SKEPTICISM .ABOUT NATIONAL HEALTH CARE 137 (1994). At least one study suggests that 
British physicians already ration health care based on factors such as: (1) the age of the 
patient; (2) the cost of necessary equipment; (3) public information about the treatment 
possibilities; (4) whether the treatment is life-saving or merely life-improving; and (5) whether 
the patient suffers from a "dread" disease. See HENRY J. AARON & WILLIAM B. SCHWARTZ, THE 
PAINFUL PRESCRIPTION: RATIONING HOSPITAL CARE 97-99 ( 1984). There is, however, still waste 
in the U.K. system. See ORIENT, supra, at 136-37. 
149 See Mark A Hall, Rationing Health Care at the Bedside, 69 N.Y.U. L. REV. 693, 713 
( 1994). Comparative study of treatment between the U.S. and Canada highlight the U.S.' 
relative propensity for surgery. See Joseph White, Health Care Reform the International Way, 
ISSUES Ser. & TECH., Fall 1995, at 34 ("Canadian heart attack victims have at least equal 
survival prospects, but 6 percent more are likely to have activity-limiting angina. The catch 
is that the American patients undergo twice the number of surgeries-paying twice as 
much-to achieve the small improvement."). 
150 Cavalier, supra note 51, at 460 (citation omitted); see ORIENT, supra note 148, at 137 ("If 
the NHS charged patients the full costs of their sleeping pills and tranquilizers, enough money 
would be freed to treat 10,000 to 15,000 additional cancer patients and save the lives of 3,000 
additional patients with kidney failure.") (citation omitted). In the U.K., "[p]rices for 
prescription drugs are regulated by the Pharmaceutical Price Regulation Scheme (PPRS)" and 
negotiated by the pharmaceutical companies, NHS, and providers. Cavalier, supra note 51, 
at 460. When biotechnology arrives fully at the commercialization stage, price restraints in 
Europe and the transaction costs of negotiating over price could restore the competitive 
advantage realized by the U.S. in the early 1990s. 
m See Cavalier, supra note 51, at 461. 
m New Era, supra note 9, at 346. 
153 See id. at 343. 
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over price in order to sell drugs throughout Europe.154 As a conse­
quence, biotechnology could make the financing of health care 
technology an even greater challenge to public health officials in the 
U.K. 
Iv. A GLOBAL APPROACH TO THE CHALLENGES OF 
COMMERCIALIZING BIOTECHNOLOGY 
International Economic Law (IEL) is a theoretical approach to 
legal scholarship responsive to industrial globalization155 and 
increasing interdependence among national economies. 156 IEL, 
which fully embodies the fundamental elements of law and 
economics, has introduced "a new, cosmopolitan perspective which 
164 See Stephen D. Moore, Still Some Bargaining to Do, WAIL ST. J. (Europe), May 6, 1996, 
at 1, available in 1996 WL 3340900 ("Except in the U.K and Germany, companies can launch 
the product only after elaborate bargaining with national authorities over pricing and 
reimbursement levels."). 
166 See Curtis R. Reitz, International Economic Law, 17 U. PA. J. INT'L ECON. L. 29, 30 
(1996) (noting that "[t]he twentieth century revolutions in communications and transportation 
have made it feasible for an entity to expand its activities geographically, virtually without 
limit . . . .  The explosive growth in the number and the reach of multinational enterprises in 
the past few years is not yet appreciated in the legal world."). 
166 See John H. Jackson, Refiections on International Economic Law, 17 U. PA. J. INT'L 
ECON. L. 17, 17 (1996) [hereinafter Reflections] (discussing the problems that government 
regulation plays on the international economy); Joel P. Trachtman, The International Economic 
Law Revolution, 17 U. PA. J. INT'L ECON. L. 33, 33 (1996) [hereinafter Economic Law 
Revolution] (discussing the relationship between public and private international law, inter­
national business law, and international economic law). Ernst-Ulrich Petersmann, a leading 
IEL scholar, has offered the following definition for International Economic Law: 
[Al conglomerate of private law (including 'law merchant' and 'transnational commercial 
law'), state law (including 'conflict of laws') and public international law (including 
supranational integration law as in the EEC) with a bewildering variety of multilateral 
and bilateral treaties, executive agreements, 'secondary law' enacted by international 
organizations, 'gentlemen's agreement,' central bank arrangements, declarations of 
principles, resolutions, recommendations, customary law, general principles of law, de 
fact.o-orders, parliamentary acts, governments decrees, judicial decisions, private contracts 
or commercial usages. 
Ernst-Ulrich Petersmann, International Economic Theory and International Economic Law: On 
the Tasks of a Legal Theory of International Economic Order, in THE STRUCTURE AND PROCESS 
OF INTERNATIONAL LAW: ESSAYS IN LEGAL PHILoSOPHY DocTR!NE AND THEORY 227, 251 (R. St. 
J. MacDonald & Douglas M. Johnston eds., 1983). For another definition, see John H. Jackson, 
International Economic Law: Reflections on the "Boilerroom" of International Relations, 10 AM. 
U. J. INT'L L. & POL 'y 595, 596 (1995) (IEL "can cover a very broad inventory of subjects: 
embracing the law of economic transactions; government regulation of economic matt.ers; and 
related legal relations including litigation and international institutions for economic 
relations."). Recognition of IEL as a field of legal study was underscored recently by a name 
change from what was formerly the University of Pennsylvania Journal of International 
Business Law to what is now the University of Pennsylvania Journal of International Economic 
Law. See Reitz, supra note 155, at 29. 
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may be used to understand and manage the international economic 
law revolution. "157 This perspective encompasses and is based 
upon the associated fields of international business law, inter­
national economic law, public international law, and private 
international law. 158 IEL relies upon the fundamental premise 
that, "[b]ecause decisions taken by people in one country affect 
people in other countries, and decisions taken in one functional area 
affect policy in other functional areas, we must determine to what 
extent and how policy formation processes can be integrated."159 
IEL "is most visible in the European Union and in the [General 
Agreement on Tariffs and Trade/World Trade Organization] systems, 
although it is growing in other regional organizations and in 
multilateral or plurilateral organizations with sectoral respon­
sibilities. "160 The EMEA is, itself, a prime example of the kind of 
multinational institution promoted by IEL to meet regulatory 
challenges that are beyond the scope of any single national economy. 
Institutions such as EMEA are founded to "allow greater com­
munications, a wider scope for exchange, increased binding power, 
and greater possibilities for enforcement. "161 Several factors make 
IEL a particularly useful tool for analyzing the shared challenges 
accompanying the commercialization of biotechnology. These factors 
include: (1) the global nature of the biomedical science comm.unity, 
which has been enhanced in the field of biotechnology by HGP; (2) 
the demand in world-wide markets for biotechnology products; (3) the 
cooperative nature of the biotechnology industry and involvement of 
multinational pharmaceutical companies in both the U.S. and the 
U.K. sectors;162 and (4) the fact that the United Nations now is 
157 Economic Law Revolution, supra note 156, at 33-34. 
158 See id. at 33. 
159 Id. at 37. 
160 Id. at 46-47; see Ref7,ections, supra note 156, at 18-24 (discussing GATI and its role in 
the international economy). But see Robert E. Hudec, International Economic Law: The 
Political Theatre Dimension, 17 U. PA. J. INT'L ECON. L. 9, 9 (1996) (stating that IEL contains 
a "'political theatre' dimension [which is defined as] the tendency of governments to adopt laws 
and agreements that create the appearance of legal solutions when in reality no solution has 
been achieved"). . 
161 Economic Law Revolution, supra note 156, at 61. As for enforcement, 
[w)hether it is a banking scandal such as BCCI, or the difficulty of harmonizing certain 
consumer or food product standards, or the differential effects of taxes, social security 
medical insurance, and labor immobility, there is today hardly any subject that can � 
said to be effectively controlled by a single national sovereign. 
Refiections, supra note 156, at 25. • 162 See Refiections, supra note 156, at 17 ("Governments find it increasingly difficult to 
implement worthy policies concerning economic activity because such activity often crosses 
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"carving itself a role in international biotechnology regulati
on. "163 • 
The following analysis is grounded in IEL and addresse� th? pubhc 
health challenges shared by the U.S. and the U.K. of revie_wing and 
regulating innovative biotechnology products and financing these 
technologies so that public health benefits may be. fully rea
lize?.164 
This analysis follows the functionalist approach which charactenzes 
the E.U.'s design and history.165 In other words, these shared 
challenges are addressed in a pragmatic fashion with the objective 
of introducing concrete proposals to meet contemporary needs. 
A. Review and Regulation Proposal 
The concept of regulatory collaboration (or "harmonization of 
law''166) is increasingly drawing recognition from both scholars and 
policy makers. 167 At the center of this concept is a belief that the 
creation of a multinational business community and maximization of 
borders in ways to escape the reach of much national government control."); Reitz, supra note 
155, at 29-30 ("Cross-border transactions between parties located in different nations can be 
and are being facilitated by laws that enable efficient negotiation and performance of exchange 
transactions."). 
168 Henry I. Miller, Biotechnology and the UN: New Challenges, New Failures, 14 NATURE 
BIOTECHNOLOGY 83 1, 831 (1996). 
164 There are, of course, other shared challenges that accompany the commercialization of 
biotechnology, such as preserving the safety of human subjects and biodiversity. See id. 
Agencies within the United Nations are introducing safety regulations that bridge the 
international science and commercial sectors in the field of biotechnology, and "[c]ertain 
agencies of the [UN] are vying with one another to become the world's 'biopolice.'" Id. 
185 See Economic Law Revolution, supra note 156, at 47 ("This functionalism asks: what do 
we need to do today, and how will we do it? It purports to eschew idealism-including one­
worldism or world federalism-rolls up its sleeves, and sets about pragmatic tasks to address 
concrete, mostly economic, needs."); see also Joel P. Trachtman, Unilateralism, Bilateralism, 
Regionalism, Multilateralism, and Functionalism: A Comparison with Reference to Securities 
Regulation, 4 TRANSNAT'L L. & CONTEMP. PROBS. 69, 74-75 (1994) (addressing international 
cooperation in securities regulation). 
196 Economic Law Revolution, supra note 156, at 61. 187 See id. at 46 ("Increasingly, it is recognized that domestic regulation of business is within 
the domain of international economic law. International economic law addresses some of these 
concerns by promoting cooperation among states and limiting competition."). Collaboration for 
greater returns is a concept long recognized by economic theorists. Consider the following il­
lustration of this principle: 
Suppose [the cattle owner's] profits could be increased by letting the cattle roam over part of the farmer's crops, thereby destroying them, but that the farmer has the legal right to fence her land against the cattle. The two then have an interest in striking a deal that allows the c�ttle to roam over part of the farmer's land. They can do so because each can be made ordmally better off by making the deal. 
Russell J:l�din, Magic on the Frontier: The Norm of Efficiency, 144 U. PA. L. REV. 1987, 1991 (1996) (c1tmg Ronald H. Coase, The Problem of Social Cost in THE FIRM .,...,.� u. �· � LAW 95, 99 (1988)). ' ' J. nr.. � lU\N!iT AND THE 
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interaction and competition between industry players will realize 
greater market efficiencies. "With the intensification of economic 
relations has come the recognition that these relations can be 
facilitated, or made more efficient, by increased regulatory transac­
tions between states in the area of international trade law and 
business regulation."168 Rather than promoting cooperation for the 
sake of cooperation, IEL promotes cooperation as a means to realize 
more of what is desirable. 169 
For believers in IEL, the establishment of the EMEA marks the 
beginning of a more promising era in public health. Ideally, the 
EMEA and FDA will compete and maximize their efficiencies to 
attract innovative health care products to their markets while they 
collaborate to eliminate duplication, to maximize resources, to reach 
reliable safety and quality assessments of innovative technologies 
without delay, and to generally minimize the risk of error while 
streamlining the review and approval processes for health care 
products.170 HGP is the model, for it has maximized efficiencies in 
biomedical science on the domestic and international levels by 
utilizing these principles of collaboration and competition.171 HGP 
has focused the science community's efforts on a single objec­
tive-gene sequencing to construct a map of the human genome that 
will serve as an invaluable shared research resource for the world­
wide biomedical science community. 172 In doing so, HGP has 
facilitated the exchange of information and notification of each 
discovery within the science community, and fostered intense 
competition between scientists who often are aware that contem­
poraries in other labs are racing to make the same discovery. 173 
IEL theorists recognize that national regulatory bodies possess 
ample domestic authority but need motivation to collaborate with 
their foreign counterparts.174 The FDA is certainly no exception. 
This need for motivation is attributable to domestic pressures 
coupled with international competition resulting from the establish-
168 Economic Law Revolution, supra note 156, at 60-61.  169 See id. at 61. 
170 See Malinowski & O'Rourke, supra note 1, at 190-92 (observing that the HGP, initiated 
by Congress in 1988-89, has prompted European countries to commence similar efforts). 
171 See id. at 191-92. 172 See id. 
178 See Malinowski & O'Rourke, supra note 1,  at 183-84 (noting that the "commer­
cializ[ation)" of the science industry has increased competition among scientists for financial 
returns). 
174 See Economic Law Revolution, supra note 156, at 45-46. 
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ment of the EMEA 175 The EMEA already has brought abo
ut 
market efficiencies both in the E.U. and globally. Within the E.U.,
 
the EMEA is drawing together resources and eliminating 
duplication.176 To the extent that the EMEA has introduced 
competition and enhanced FDA efficiency, it also has benefitted the 
domestic interests of the U.S. The fact that the FDA and EMEA 
each have a counterpart and competitor should continue to improve 
the efficiency and effectiveness of drug approval in both 
countries.177 This improvement is a real possibility due to the 
notorious inefficiencies and other shortcomings in the drug review 
and market approval systems of both the U.S. and the U.K. 178 In 
the U.S., "recent studies suggest that regulatory delays may have a 
negative impact on patient life expectancy and quality of life. . . .  
[O]n balance research does suggest that regulatory systems in other 
industrialized nations achieve a generally safe drug supply while 
avoiding some of the delay of the FDA process."179 Pre-EMEA 
inefficiencies in the U.K. are made evident by what the EMEA 
process is expected to accomplish. The mission of the EMEA is to 
enforce reliable quality controls while enabling companies to obtain 
E.U. market access for their products at a savings of both con­
siderable time and forty percent of the cost of obtaining approval 
through the traditional multi-state system.180 
Supporters of the FDA might point out that, at least to some 
extent, the FDA is a victim of its own success. After decades of 
independence and authority mushrooming out of fear of mistakes, 
175 See Bent & Booth, supra note 18, at C3 (attributing FDA's willingness to participate in 
ICH "to a fear that the [FDA] may lose its status as the world's pre-eminent drug regulatory 
�y"). Pursuant to one bill, FDA approval would be mandated when a drug offers significant 
llll�rovement over other approved products and has been approved by the EMEA or the 
national U.K. authority and the U.S. fails to meet a statutory deadline See S 1477 104th 
Cong. § 404 ( 1995). · · ' 
::: See �DA Reform� supra note 51, at 2018-19. 
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e FDA more responsive to popular demand for beneficial 
e am alillllg i ro e as a guarantor of safety ") 178 See id. at 2014-15. · · 179 Id. (discussing research findin f h c 
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at �n average cost of $359 million.") (citing Elizabeth 
L.J. 203 n.2 Ci995)). 
anzation -The Drug Approval Process," 50 FOOD & DRUG 
18Q s ee supra notes 106-07 and accompanying text. 
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such as the U.K.'s thalidomide experience 181 the FD A' th ·t . b . h k d b ' 
n.s au on y 
now is eing c ec e Y public excitement over the prospects of 
biotechnology. 182 FDA supporters may further contend that the 
"cultural icon"183 status of DNA and shortsightedness already put 
enough public and political pressure on the FDA and EMEA. 184 An 
international race to review and approve a multitude of biomolecular 
technologies generated by astonishing advances in biomolecular 
science, it might be added, could potentially endanger the very public 
that the FDA and EMEA are obligated to protect. 185 
ffitimately, the review and market approval of health care 
technology should not be unduly burdensome nor a domestic matter 
subject to undue pressure from shortsighted political, industrial, and 
public influences. The mission of both the FDA and EMEA is to 
assure quality and safety, and to protect consumers made especially 
desperate and vulnerable by illness.186 In light of the new 
181 See FDA Reform, supra note 51, at 2012; ABRAHAM, supra note 49, at 62-63, 66, 82. Prior 
to 1962, the FDA assessed only the safety of new drugs; their effectiveness was not considered. 
All of this changed with the discovery in 1961 by doctors in Europe that thalidomide, widely 
prescribed to combat morning sickness, was responsible for a significant number of birth 
defects. See FDA Reform, supra note 51, at 2012. The enactment of drug reform legislation 
followed. See id. (citing PETER TEMIN, TAKING YOUR MEDICINE: DRUG REGULATION IN THE 
UNITED STATES 123 (1980)). 182 The public is demanding access to the technology they have been reading about. As 
recognized by Professor Annas, "[t]he gene has become more than a piece of information; it has 
become 'a cultural icon, a symbol, almost a magical force."' George J. Annas, Genetic Prophecy 
and Genetic Privacy, TRIAL, Jan. 1996, at 19, 24-25 (quoting DoROTHY NELKIN & M. SUSAN 
LINDEE, THE DNA MYSTIQUE: THE GENE AS A CULTURAL ICON 2 (1995)); see Richard Saltus, 
Sounding the Alarm, BOSTON GLOBE MAG., May 26, 1996, at 14, available in 1996 WL 6862982 
("No longer merely a scientific schematic, it is now a staple of pop culture. It appears time and 
again in op-ed pieces, newspaper and magazine articles, and books that tackle the thorny 
dilemmas of the genetic revolution."). Dr. Richard C. I.ewontin, a Harvard scientist and 
affiliate of the Council for Responsible Genetics, is critical of present priorities in gene research 
and has coined the term "genomania," meaning "the idea that almost everything-a baby's chin 
or nose, someone's personality quirks, or a preponderance of men in positions of power--can 
be explained by genes." Id. at 30-31. But see Richard Saltus, Early Alzheimer's: Do You Want 
to Know?, BOSTON GLOBE, July 3, 1995, at 39 ("Recently developed gene tests for Huntington's 
disease and for inherited predispositions to breast cancer and other cancers have rai�ed this 
issue for an increasing number of families. If any conclusion can be drawn thus far, it's that 
people are more hesitant and ambivalent about learning their genetic destiny than anyone 
expected."). 188 Annas, supra note 182, at 25. 184 See Malinowski & O'Rourke, supra note 1, at 210. 185 The concern "is that adoption of international st�dards will inevita��y lea.d to a 
weakening of U.S. standards, and perhaps even lead to a race to the bottom, in which the 
FDA and EMEA compete to mollify domestic criticism or favor local manufacturers." Bent &
 
Booth, supra note 18, at C3 (quoting FDA Reform, supra note 51, at 2024). · 
" 
186 See FDA Reform, supra note 51, at 2010, 2018. As observed_ �y P�o�essor Pa� Starr, [t]he very circumstances of sickness promote acceptance of [physICians l Judgment. PAUL 
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constraints being placed upon many providers under manag�d care, 
it is less prudent now than in the past to rely upon providers to 
protect consumers.187 Although they should not be isolated from 
public and political pressures, the FDA and EMEA must not . be thrown to these influences and reduced from consumer protection 
agencies to mechanisms primarily for domestic econo�c pr�sperity. 
The products at issue include unprecedented diagnostics and 
therapeutics for cancers, AIDS, and other causes of immense human 
suffering. Accordingly, they necessitate efficient review, and the 
biotechnology industry innately carries a significant amount of 
influence.188 Assuming reasonable agency accountability is effected 
through dissemination of accurate information to the public, 189 
STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE 5 (1982). 
187 See FDA Reform, supra note 51, at 2010 <iPJhysicians and, increasingly, managed-care 
insurers are often in tension with the FDA over who is best placed to make particularized 
judgments about a drug's safety and effectiveness. Although the FDA rigorously scrutinizes 
all new drugs before approval, the agency allows doctors wide latitude to prescribe drugs 
approved for one particular use in unapproved ('unlabeled') ways to treat other conditions."). 
It is interesting to note that, "[f]or most of the FDA's history, the agency was charged only with 
screening out unsafe drugs; determinations of efficacy in prescription drugs were left to 
prescribing physicians." Id. at 2019 (citing Peter B. Hutt, The Regulation of Pharmaceutical 
Products in the USA, in PHARMACEUTICAL MEDICINE 211, 217 (Denis M. Burley et al. eds., 2 
ed. 1994)). See also PETER TEMIN, TAKING YOUR MEDICINE: DRUG REGULATION IN THE UNITED 
STATES 123, 127-28 (1980) (stating that doctors prescribe drugs based on the "customs of the 
medical community," rather than their "therapeutic effect"); New Era, supra note 9, at 351 
(noting that physicians who belong to managed care networks feel pressure to "'cut corners 
or . . .  delay or omit diagnostic tests or therapeutic procedures"') (quoting Orentlicher, supra 
note 146, at 158). 
188 See TEMIN, supra note 187, at 55. Historically drug manufacturers have "had to fight 
for their gains. To curb the FDA's power to classify drugs, [they] had to enter into explicit 
negotiations. Their success in these negotiations is hardly surprising." Id. 
189 The FDA's authority to regulate advertising of health care technologies has not and 
cannot stop researchers from informing the public about. their genetic discoveries nor the 
general media from reporting on these highly newsworthy advances. See supra note 182 (citing 
media sources reporting and commenting on the so-called "genetic revolution"). Although 
advertising laissez faire is a troubling proposition, according to some accounts, FDA officials 
have all the power and discretion they need, and this discretion is enhanced by the ambiguity 
of the regulations they enforce. See, e.g. , James G. Dickinson, Will Anybody Sue FDA?, MED. 
MARKETING & MEDIA, Oct. 1, 1993, at 100, 101 ("The Food, Drug and Cosmetic Act's failure 
to address pharmaceutical marketing activities that are neither 'advertisements' nor 'labeling' 
created the gray zone in which both industry and FDA take liberties. Congress simply failed 
to foresee the innovations that modern communication technologies could spawn."). As 
explained by Dr. Dickinson, 
[a]dvertising alone is defined as 'commercial speech' and is thus subject to less First 
Amendment protection than labeling or non-commercial speech. But FDA has been able 
to tie advertis�g's statu�ry �ependence on the content of approved labeling to a broad �ay of 'lab�hng' matenals m .s�ch a way that companies have no freedom of speech rights �hen it comes to advertismg prescription drugs, compared to the way in which those rights are commonly understood and interpreted by the courts for other industries. 
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ongoing public demand for health care technology should keep the 
EMEA and FDA in check. 190 The alliance nature of the biotech 
industry and privatization of health care R&D are additional 
assurances that these agencies will not become distant, independent, 
and nonresponsive.191 In fact, the alliance nature of the biotech­
nology industry may have weakened the FDA's most important 
resource for legitimizing tough and controversial decisions. 192 
Historically, the FDA has relied upon the top echelon of medical 
academia to justify its controversial stances with industry.193 Now, 
however, influential non-profit research centers, academic 
institutions, and the world's top biomedical scientists all have a 
direct and meaningful stake in the success of the biotechnology 
Id. at 102 (quoting BAD PRESCRIPI'ION FOR THE FIRsT AMENDMENT: FDA CENSORSHIP OF DRUG 
ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)). Dr. Dickinson alleges that 
"[b]ecause FDA has excessive coercive power in its ability to approve an advertiser's products 
for market, and Congress has shown no interest in balancing FDA's First Amendment 
incursions, the regulation of drug advertising and promotion should be handed over to the 
Federal Trade Commission." Id. at 103-04. Dr. Dickinson contends that the FDA's definition 
of "deception" is "the basis for the mischief created by the FDA's regulation of advertising." 
Id. (quoting BAD PREsCRIPTION FOR THE FIRST AMENDMENT: FDA CENSORSIIlP OF DRUG 
ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)). Dickinson noted that "[ t]he [FDA] 
says ads or promotional materials are deceptive unless they contain 'fair balance.'" Id. (quoting 
BAD PRESCRIPl'ION FOR THE FIRST AMENDMENT: FDA CENSORSHIP OF DRUG ADVERTISING AND 
PRoMOTION (Richard T. Kaplar ed. 1993)). In practice, according to Dr. Dickinson, "'any 
message promoting some pharmaceutical must also present virtually all negative information 
about the product . . . .  "' Id. (quoting BAD PRESCRIPI'ION FOR THE FIRST AMENDMENT: FDA 
CENSORSHIP OF DRUG ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)). Dickinson 
sets forth the following proposals for reform: 
FDA should (1) cancel all recent initiatives restricting promotion of off-label uses; (2) allow 
manufacturers to advertise any reasonable claim for which reliable scientific evidence 
exists; (3) abolish the 'brief summary' requirement for consumer advertising; and (4) allow 
unrestricted advertising of drugs, subject only to regulation for 'falsity' but not for 
'deception' as currently defined. 
Id. (citing BAD PRESCRIPTION FOR THE FIRST AMENDMENT: FDA CENSORSHIP OF DRUG 
ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)). Nevertheless, there also is 
evidence that hyping of health care product features by their manufacturers is a pervasive 
problem: 
So endemic is the practice of hyping product features the facts clearly don't support that 
FDA deputy commissioner Mary K. Pendergast, speaking in October 1994 before the 
House Subcommittee on Regulation, Business Opportunities, and Technology, was moved 
to uncharacteristically straightforward language. "Promotion of unapproved uses by 
company sales representatives," she stated, "is a major problem." 
Greg Critser, Oh, How Happy We Will Be: Pills, Paradise, and the Profits of the Drug 
Companies, HARPER'S MAG., June 1996, at 39, 47. 190 See FDA Reform, supra note 51, at 2024. 191 See id. at 2010. 
192 See id. at 2014-15. 
193 See id. at 2016. 
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industry due to the privatization of medical R&D and . the alliance 
nature of the industry.194 • • • 
Ideally, domestic pressures and international competi�10.n will 
bring the resources of the EMEA and FDA together to maxmnze the 
speed and quality of their review.195 This may already be hap­
pening, for the U.S., Japan, and the E.U. (eve� prior. to the fo�ding
 
of the EMEA) have been working to harmomze their respective re­
quirements for new drug research and applications: 
The EU, Japan, and the United States, which together 
account for most of the world's drug consumption, par­
ticipated in the International Conferences on Harmonization 
in 1991 and 1993. These conferences examined regulatory 
differences between the three blocs and began to draft 
international guidelines on procedure, quality, safety, and 
efficacy to be incorporated into each country's legal scheme 
because pharmaceutical industry and government regulators 
agree that harmonization of drug authorization is neces­
sary.196 
"The fundamental goals of the ICH are to reduce the costs associated 
with gaining regulatory approval . . .  and to increase patient access 
to new drugs. . . . The FDA has [actively participated] in the 
harmonization process, "197 and the establishment of the EMEA 
UM See supra notes 21-22. See generally Malinowski & O'Rourke, supra note 1 (discussing 
numerous examples of scientists from public and private universities, as well as the 
universities themselves, entering into joint ventures with genotech firms). 
196 The presence of the EMEA, which now oversees the world's largest integrated phar­
maceutical market, should be enough to compel FDA collaboration. See Eric M. Katz, Europe's 
Centralized New Drug Procedures: Is the United States Prepared to Keep Pace?, 48 FOOD & 
DRUG L.J. 577, 578-79 ( 1993). "The existence of this huge integrated market threatens to 
undermine the FDA's position of regulatory leadership, and U.S. patients ultimately may suffer 
from an even greater 'drug lag' if [the U.S. market becomes a secondary priority and] 
pharmaceutical manufacturers tailor their clinical research and new drug applications to 
satisfy EMEA standards." FDA Reform, supra note 51, at 2021. 
196 Cavalier, supra note 51, at 466 (citations omitted); see Bent & Booth, supra note 18, at 
Cl, C3-C4. A comparison of the drug review and approval processes of the U.S., Europe, and 
Japan is presented in Rosemarie Kanusky, Comment, Pharmaceutical Harmonization: 
Standardizing Regulations Among the United States, the European Economic Community, and 
Japan, 16 Hous. J. INT'L L. 665 (1994). 
197 Bent & Booth, supra note 18, at Cl, C3 (citation omitted). The ICH process consists of 
five steps: ( 1) the expert working group "forwards a consensus draft of a guideline . . .  to the 
steering committee"; (2) "the steering committee transmits the draft to the (U.S., U.K., and 
Japanese] regulatory agencies for formal consultation"; (3) "a designated rapporteur amends 
the dr� document to [incorporate] comments"; (4) "the final draft is endorsed by the steering 
�o���tee"; and (5) the final document is implemented domestically by the members. Id. at 
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should ensure future participation.198 Also, the FDA has entered 
into several memoranda of understanding with foreign regulatory 
bodies regarding the monitoring and inspection of foreign data199 
and, in some instances, the FDA is permitting approval of drugs 
based solely on foreign clinical data. 200 "More recently, the EMEA 
has stated that it will continue to explore the development of 
harmonization and mutual recognition programs with the United 
States and Japan."201 
Collaboration and standardization of product review and approval 
could further join the U. S. and E.U. industries, thereby enabling 
market forces to work more effectively on a global level. 202 First, 
if a single, carefully designed clinical trial (accompanied by necessary 
post-marketing checks) could result in approval on the major world 
markets, at least theoretically, the costs of the resulting products 
would be lower and more resources would be made available for 
R&D. 203 Second, eliminating barriers between markets could make 
it economically feasible to manufacture drugs otherwise designated 
orphan drugs. 204 Third, a more unified world market may be the 
best way to distribute the philanthropy of the multinational phar­
maceutical companies which, though sporadic, has been substantial 
198 "The agency to date has published 39 notices concerning various topics addressed by the 
ICH, as well as three notices concerning related harmonization efforts." Bent & Booth, supra 
note 18, at C3 n.12 (citing 60 Fed. Reg. 53078 (1995) (Policy on Standards); 60 Fed. Reg. 3 1485 
(1995) (International Memorandum of Understanding, New Compliance Policy Guide); 60 Fed. 
Reg. 25920 ( 1995) (Viral Testing)). FDA Commissioner Kessler has stated that biotechnology 
drugs may be a means to harmonize regulations since their novelty sets them apart. See id. 
at C3 n.10 (citing Keynote Address by Commissioner David A. Kessler, M.D. at the Proceedings 
of the Second International Conference on Harmonisation (Orlando, Fla. 1993)). 
199 See Philip B. White, International Memoranda of Understanding on Inspections, 49 FOOD 
& DRUG L.J. 171, 171 (1994) (stating, however, that these memoranda have been problematic 
in practice). 
200 See, e.g. , Food and Drugs, 21 C.F.R. § 314. 106 ( 1995) (explaining the requirements of 
foreign data as the sole basis for marketing approval). 
201 FDA Reform, supra note 51, at 2021; White, supra note 199, at 171 (stating that 
"[m)utual agreements with other countries in the area of GMPs [international good 
manufacturing practices] are an important priority for . . .  the FDA"); see Reguly, supra note 
51, at 1 ("In time, [the EMEA] may even emerge as part of a super-regulator, linked with the 
FDA and Japan to create an international agency that would allow pharmaceuticals groups to 
clear medicines in three of the world's biggest markets in one go."). 
202 See Cavalier, supra note 51, at 447. 
203 See id. 
204 To be designated an orphan drug means that the anticipated consumer market for the 
drug is too small to justify production without market exclusivity under programs such as the 
U.S. Orphan Drug Act. See Orphan Drug Amendments of 1988, 21  U.S.C. §§ 360aa, 360bb, 
360ee (1988); 42 U.S.C. § 236 (1988). See generally Cavalier, supra note 51 (discussing the 
history of the Orphan Drug Acts in the U.S., Japan, and Europe). 
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in recent years. 205 This possibility is underscored by the fact that P
�
arma�eutical corporations also are joining the U.S. and the U.K. h1otech industries by entering into multiple alliances with biotech counte�parts on both sides of the Atlantic.206 Fourth, collaboration for review and approval also could result in uniform standards for lab�ling and patient information. 207 This already has been achieved to some extent in the E.U.208 
More generally, mutually beneficial alliance formation between the 
U.S. and the U.K. biotech industries already is apparent.209 
Greater market unification and alliance freedom on a multinational 
level should maximize intellectual and financial resources. 210 The 
rationale is that expanded cooperation eliminates duplicative 
research and, therefore, better concentrates the energies of research-
205 See, e.g., Luther Turmelle, Merck & Co., Paul Newman Win Humanitarian Awards, 
COURIER NEWS, Apr. 23, 1993, at l, available in 1993 WL 3181546 ("Merck and its 
philanthropic arm, the Merck Company Foundation, have donated more than $153.4 million 
in cash and products between 1990 and 1992."); Company to Give Medicine to Uninsured Poor, 
N.Y. TIMES, Aug. 15, 1993, § 1, at 1, available in 1993 WL 2111517 ("Pfizer Inc. announced on 
Aug. 14, 1993 that it would offer 11 of its products free to community health centers that 
provide medical care to poor patients who have no health insurance. The company estimated 
the program would cost $10 million to $12 million in its first year."). 
20s See Cavalier, supra note 51,  at 458 ("[V]irtually all pharmaceutical companies have 
indigent patient programs that provide free drug therapy to those who specify in writing that 
the drug will not be reimbursed by Medicaid or insurance."). 
207 See Eyckmans, supra note 29, at 36. 
20s Specifically, back in March 1992, 
the (E. U.] Commission adopted rules to standardize labeling and harmonize the 
requirements for patient information. These rules spell out the information that must be 
included on the product's packaging and in the-now compulsory-patient leaflet. This 
information must be provided "in clear and understandable terms" and in the official 
languages of the member states where it is marketed. 
Id?.iw British pharmaceutical companies also merge with U.S. firms to take advantage of their 
dvanced technologies, and vice versa. The desire for computer-designed molecules led Glaxo a
le to purchase Affymax for $533 million in January, 1995, and led to Oxford Molecular's p 
greement to purchase CAChe Scientific, Inc. earlier that month. See Start-ups, supra note 
;4 at 372. The computer technology offered by the U.S. firms allowed pharmaceut�cal ' 
chers to use "computer-designed molecules, rather than those produced through chemical 
:::s
�
mentation, as the basis of a new gen�ration of drugs." Id. Also, several smaller British 
t t- p biotech ventures have merged with U.S. firms to take advantage of U.S. venture 8 a�





t of a merger between Scotland-based Scotgen and California's Vasocor, Inc., was able t e res · fi · l' · l t · l S id 
· $7 million in capital from U.S. mvestors or use m c rmca na s. ee . 
to {i!1� Manning Gilbert Warren III, Global Harmonization of Securities Law: The 
h .  
ee 
nts of the European Communities, 31 HARV. INT'L L.J. 185, 225 (1990) (stating that Ac ieveme
k ts combine cost of capital decreases resulting in an increase of financial resources). when mar e ' 
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D 
. t 211 ers and the funds that support them on specific R& proJ eC s. 
Furthermore, unifying the world markets to better enable the most 
suitable allies to find each other can only help to stabilize investor 
interest212 and improve science and product applications.213 This 
already is happening within the E.U. "Certainly, the statistics 
suggest that E.C. firms are actively seeking new sources of com­
petitive strength in domestic and international markets and are 
more willing than in the past to conclude alliances that promise an 
infusion of international capital and new ideas. 
"214 
There should be two overarching objectives to the review and 
regulation of biotechnology products-realizing the most economical 
use of human and other resources and expediting patient access to 
beneficial products without compromising safety. Many of the 
products at issue in the biotech sector provide the means to alleviate 
tremendous human suffering, and the importance of realizing such 
an improvement to public health certainly is as global as the 
challenges accompanying the commercialization of biotechnology. 
211 See Joseph G. Contrera, The Food and Drug Administration and the International 
Conference on Harmonization: How Harmonious will International Pharmaceutical Relations 
Become?, 8 ADMIN. L.J. AM. U. 927, 957 (1995) (stating that harmonization will allow countries 
to spend their money more productively and avoid costly duplicative research and develop­
ment). 
212 See Barriers, supra note 31, at 572. For the U.K, alliances with more mature U.S. 
counterparts could help to stabilize investment appeal while its biotech industry moves 
through the extremely volatile no-products-on-market stage. See id. 
213 U.S. antitrust policy is supportive of cooperation for research endeavors. See Cooperative 
Research Act, 15 u.s.c. §§ 4301-02 (1994); U.S. DEp'T OF JUSTICE ANTITRUST ENFORCEMENT 
GUIDELINES FOR INTERNATIONAL OPERATIONS (1988), reprinted in 4 Trade Reg. Rep. (CCH) 'II 
13,109. IEL, the strength of which rests in collaboration, is also an approach to overcome the 
limitations of domestic antitrust policy meaning, among other things, the doctrine of comity 
and the act-of-state doctrine. See 1 PlllLLIP AREEDA & DONALD F. TuRNER, ANTITRUST LAW: 
AN ANALYSIS OF ANTITRUST PRINCIPLES AND THEIR APPLICATION 'II 239, at 271-76 ( 1978 & 
Supp. 1996) (discussing American antitrust policy towards foreign restraints on U.S. 
Commerce). Collaboration between the FDA and EMEA should include enforcement of 
antitrust principles to prevent industry over-consolidation orchestrated by the multinational 
pharmaceutical industry. Also, national industry influence over both the FDA and its 
European counterparts, fostered by the incestuous nature of the science community, has given 
credence to a theory that these agencies have, to some extent, been "captured" by industry. 
See ABRAHAM, supra note 49, at 22-23 (stating that "a regulatory commis­
sion . . .  [i]nitially . . .  tends to be aggressive and adversarial towards its regulatees, 
but · . .  [e]ventually it is progressively 'captured' by, and comes to share the perspectives of 
the regulated industry"). The danger that such influence could be used to exploit access � 
world markets must be offset by maintaining checks and balances between the FDA and 
�EA despite collaboration to eliminate duplication and establish uniform, scientifically 
reliable standards. See AREEDA & TuRNER, supra. 
214 Paul J. De Rosa, Cooperative Joint Ventures in European Community Competition Law 
41 BUFF. L. REV. 993, 1044 (1993). 
• 
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The removal of unnatural barriers between the markets, made 
accessible through FDA and EMEA collaboration, would bring both 
the U.S. and the U.K. closer to realizing the full public health 
potential of biotechnology. 
B. Health Care Finance Proposal 
The spread of managed care in the U.S. suggests at least some 
recognition by public health officials that the law of economics 
governing consumer goods, such as food, shelter, and transportation, 
applies to health care.216 In fact, because health care is part of the 
commercial sector (the largest industrial sector in the U.S.), the law 
of economics is a means to maximize the allocation of health care 
resources and improve public health. 216 Similarly, fundamental 
differences between the U.S. and the U.K. health care systems make 
comparative law useful for identifying the relatively beneficial and 
detrimental features of each system. As discussed in Part II of this 
Article, the inundation of health care capabilities from advances in 
biotechnology, absent a parallel increase in the resources allocated 
to health care, will make care rationing217 and tragic choices more 
prevalent in both the U.S. and the U.K.218 As suggested above, 
215 See ORIENT, supra note 148, at 151-59; New Era, supra note 9, at 360 (proposing 
"numerous reforms and uses of legal and regulatory mechanisms to promote socially 
responsible allocation of health care resource and to ensure that capitation does not result in 
substandard care"). 
218 See David L. Kaserman, Reimbursement Rates and Quality of Care in the Dialysis 
Industry: A Policy Discussion, 8 ISSUES LAW & MED. 81, 97-99 (1992-93). "[H]ealth care 
markets are not exempt from the laws of economics. The sooner public policy begins to 
recognize this fact, the sooner we can begin to resolve these problems through more sensible 
regulatory approaches." Id. at 99. See ORIENT, supra note 148, at 1 73-85 (stating that 
guidelines are necessary to contain costs and to ensure quality). For discussion of the size and 
growth of the U.S. health care industry, see Ross PEROT, INTENSIVE CARE (1995). 
217 Presently in the U.S., there is a call for universal coverage accompanied by recognition 
of the need for graduated care-as made evident by a recent survey ofhealth policy specialists. 
See Peter J. Howe, Poll: Health Care Will be a Key Election Issue, BOSTON GLOBE, July 15, 
1996, at A5. While 83% of those surveyed said that the country should strive to provide 
universal health coverage and 62% said they want universal coverage by the year 2000, only 
27% supported equal access to the same quality of care regardless of ability to pay. See id. 
218 See supra Part III.B (discussing the increased costs associated with new advances in 
medical technology). Excluding elective procedures, virtually all cost containment measures 
in the field of medicine decrease quality of care for individuals and increase mortality rates. 
See Kaserman, supra note 216, at 82 ("Indeed, such trade-offs are inescapable in a world of 
limited resources."). This resource dilemma associated with advances in medical technology 
is vividly illustrated by new "cocktail" AIDS therapies which involve the combination of a 
series of drugs. See Richard A. Knox, AIDS Remedies Gi�e Little Hope to World's Poor, BOSTON 
GLOBE, July 14, 1996, at 1, available in 1996 WL 6869331 [hereinafter Little Hope] ("The gap 
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IEL is an
. 
especially useful approach to this problem, for the 
challenge is shared by the U.S. and the U.K. and arises out of 
globalized science and industry sectors.219 
The myriad of biotechnology capabilities now reaching commerce 
cannot be made sufficiently available to maximize improvements to 
public health without cost-benefit analysis.220 "Theoretically, there 
is an efficiency frontier or lower boundary that, given current 
technology, traces out a locus of minimum expenditures for a given 
number of deaths or a minimum number of deaths for a given 
expenditure."221 Finding the balance between per-patient resource 
allocation and quality requires an intensive inquiry and sizable 
transaction cost (meaning the consumption of considerable resources) 
regardless of the particular features of the health care system. 222 
between the world's haves and have-nots widened with each report about the new therapies, 
which hold the virus in check with from two to four costly drugs."). This therapy proved so 
effective in clinical trials that the study was concluded prematurely on the grounds that 
"patients on experimental therapy were doing so much better that it became unethical to 
withhold it from other study subjects." Richard A. Knox, Success of a New AIDS Treatment 
Brings Study to Early End, BOSTON GLOBE, July 24, 1996, at A3, available in 1996 WL 
6870599. The "[t]riple-drug treatment can cost $20,000 a year and more, plus the expense of 
regular blood tests at $150 to $250 apiece." Richard A. Knox, Successes Offer Hope on AIDS, 
BOSTON GLOBE, July 7, 1996, at 1, available in 1996 WL 6868464 [hereinafter Successes Offer 
Hope]; see Brian MacQuarrie, Treatments for AIDS Met by Hope, Wariness, BOSTON GLOBE, 
July 15, 1996, at Bl ("The high cost of the treatment, estimated to be as much as $20,000 
annually per person, concerns physicians and gay activists who question whether the public 
will be willing to help foot the bill for such expensive therapy."). Presently, "no more than 10 
percent of the estimated 600,000 to 900,000 Americans with HIV infections are now on 
aggressive treatment, raising a question of whether society will be willing to spend the billions 
of dollars it would take to carry out the new treatment guidelines." Successes Offer Hope, 
supra, at 1. "Already, questions are being raised
.
about who should be t�ate� and wh�n, an?, 
about the multibillion-dollar potential cost of making the new drug therapies widely available. 
Id. In the "new world" of managed care, '"[h]eaven help your bottom line if during your 
contract year a new drug or expensive laboratory test is approved, as you will have to absorb 
this by a reduced income or by delivering fewer services th�n you had plan�ed to other 
patients.'" Little Hope supra at 1 (quoting Dr. Paul Volberding of San Francisco General 
Hospital). See generally C�RESI & BOBBITT, supra note 13 (discussing the difficulty that 
cultures around the world must endure due to the scarcity of resources). 
219 See supra notes 162-63 and accompanying text. 
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ent i ormation . . .  [;] (5) orce 
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• 
• reimbursement rates to treatment ownership of dialysis clinics[;] (6) the feasibility of tying
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This is attributable to the need for substantial input from experts 
and consumers with varying perspectives, the premium on accuracy 
necessitated by the emotionally charged nature of allocating health 
care resources, and the fact that the outcomes will constitute a basis 
for denying treatment. Also, reliable quality assessment focuses on 
outcomes and involves thoughtful inquiries made in an intelligent 
manner, which necessitates compilation and interpretation of 
considerable follow-up data.223 
The U.S. health care system, a "prepaid system for con­
sumption, "224 is particularly ill-suited for such determinations-as 
has been made apparent by the legal, professional, and social 
resistance to the Oregon plan225 and the performance of the U.S. 
health care system in comparison to the systems of other in-
duration[;] and (7) society's willingness [or unwillingness] to devote additional resources 
to the ESRD program. 
Id. at 95. The high transaction costs of quality and cost-benefit analysis are exemplified by 
the recognized evidentiary difficulties associated with efficiency analysis in the context of 
antitrust law: 
These evidentiary problems led then-Professors Posner and Bork, the two most influential 
exponents of the Chicago School's efficiency-based antitrust analysis, to argue against 
recognizing any kind of an efficiencies defense. Although the two share the view that 
mergers are generally efficiency-enhancing, they have argued against an efficiencies 
defense out of a belief that courts lack the tools to measure efficiencies and gauge their 
effect on prices against the countervailing anticompetitive propensities of a merger. 
Joseph Kattan, Comment, Effi.ciencies and Merger Analysis, 62 ANTITRUST L.J. 513, 520 (1993-
94); see RICHARD A. POSNER, ANTITRUST LAW: AN ECONOMIC PERSPECTIVE 112 (1976) (noting 
that "the measurement of efficiency [is] an intractable subject for litigation"); ROBERT H. Boru<, 
THE ANTITRUST PARADOX: A POLICY AT WAR WITH ITSELF 126 ( 1978) (noting that it is "the 
productive efficiency factor that renders the problem utterly insoluble"). 
223 For more health care cost-effectiveness materials and citations to other sources, see 
generally, NEW ENGLAND REGIONAL GENETICS GROUP, COST-BENEFIT/COST-EFFECTIVENESS 
ANALYSES IN GENETICS, Mar. 30, 1996 (These materials were distributed during a conference 
held at the Whitehead Institute for Biomolecular Research in Cambridge, MA and are on-file 
with the author.). 
224 ORIENT, supra note 148, at 237-45 (arguing that insurance is for catastrophes, and t�at, 
rather than insurance, the U.S. has a "prepaid, tax subsidized plan[] for the use of medical 
services"). 
226 These impediments were explained by Dr. Michael Garland in his presentation, Role of 
Economics in Setting Health Practices and Priorities: The Oregon Plan, at the Cost­
Benefi t/Cost-Effectivene�s Analysis in Genetics conference sponsored by the Social and Ethical 
Concerns Committee of the New England Regional Genetics Group. See NEW ENGLAND 
REGIONAL GENETICS GROUP, supra note 223 (transcript on file with author). The legal 
prohibition to quality of life considerations according to the HCFA's in.
te!'J?retation. of the 
Americans with Disabilities Act (ADA), 42 U.S.C. §§ 12112-12113 (1994), is discussed m New 
Era, supra note 9, at 339-40 & n.64. For comparison, consider that the U.K. and Canada have 
acknowledged the need to engage in cost assessment. See generally ORIENT, supra no.te .
148 
(highlighting some pros and cons of both the British and Canadian system of sociahzed 
medicine). 
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dustrialized countries. 226 One of the significant differences be­
tween the U.S. and the U.K. health care systems is that, for decades, 
U.S. health care providers have been both patient advocates for care 
without concern for costs and private practice entrepreneurs.227 
Although entrepreneurialism generally has a positive impact on 
quality and efficiency, it has not had this effect in a prepaid health 
care system that lacks specific quality requirements and compensates 
physicians according to the amount of health care resources they 
expend. When physicians have personally invested in specialized 
training and medical technology for advanced procedures, too often 
there have been conflicts of interest on the part of physicians that 
have encouraged the wasteful expenditure of society's health care 
resources. 228 In some instances, despite the tremendous con­
sumption of health care resources in the U.S.,  perverse rate-setting 
incentives and the absence of firm quality of care standards have 
226 See White, supra note 149, at 34 ("Every other industrialized nation guarantees a high 
standard of care to virtually every citizen, at much lower cost than that of the U.S. system."). 
227 See New Era, supra note 9, at 334-47. It is important to note, however, that managed 
care is bringing about tremendous change in the U.S., including consolidation within the health 
care industry and the buyout of private physician practices. See Phillip R. Kletke et al., 
Current Trends in Physicians' Practice Arrangements: From Owners to Employees, 276 JAMA 
555, 555 (1996) (reporting that "[b]etween 1983 and 1994, the proportion of patient care 
physicians practicing as employees rose from 24.2% to 42.3% . .  ., the proportion self-employed 
in solo practices fell from 40.5% to 29.3% . . .  , and the proportion self-employed in group 
practices fell from 35.3% to 28.4%"). 
228 The impact of perverse incentives on the U.S. health care system have been illustrated 
through a case study addressing end-stage renal disease (ESRD). See Kaserman, supra note 
2 16, at 85-86. Reimbursement levels for ESRD fell approximately 64% during the 1980s and 
early 1990s. See id. at 82. The case study made evident that these savings were attributable 
primarily to shortening the duration of patients' ESRD dialysis running times. See id. This 
lowers costs by allowing "existing machines [to] be used more intensively" and "labor costs per 
treatment [are] reduced commensurately." Id. at 83. Under a "fixed price per treatment" 
payment scheme, ESRD "clinics' profits are unambiguously increased with reduced treatment 
times." Id. at 83-84. However, "[e]mpirical evidence suggests that lower treatment duration 
causes increased mortality among dialysis patients." Id. at 84 (citing Philip J. Held et al., 
Mortality and Duration of Hemodialysis Treatment, 265 JAMA 871 (1991)). "Therefore, a 
definite trade-off exists between profitability and quality of care in the dialysis industry." Id. 
The conclusion reached by Kaserman was that "there is strong evidence to suggest that the 
cost savings attributable to reduced reimbursement rates are being gained at the expense of 
patients' lives." Id. at 82. It is important to note, however, that this case study was based 
upon data gathered in the 1980s and early 1990s. This was prior to the advent of widespread 
managed care, and at a time when a "substantial portion of dialysis clinics [were] owned by 
the physicians that [ran] them." Id. at 84. "These physicians/owners control[led] patients' 
[dialysis] running times through the treatment prescriptions they [wrote]." Id. Under 
capitation, however, physician compensation (as well as their very employment by a managed 
care system) still may be tied to profitability. See New Era, supra note 9, at 348. 
166 Albany Law Re
view [Vol. 60 
. b t dard treatment. 
229 In addition, there is 
resulted m su -s an · 11 
remarkable inconsistency in both treatm�
nt and coverage, especia y 






roviders are civil servants employed by the 
NH . � e mem-
be
rs of the U.S judiciary, who have a professional 
obligat1�n. 
to t�e 
parties before them as well as to the judici� its�
lf, phys1Cians m 
the U.K. are professionally obligated 2
:;o their patients and to the 
health care system they are a part of. . . 
Just as the U.K. industry may benefit from th� U.S. expenenc
e 1n 
allocating capital and joining the science and industry sectors �
o 
build a biotech industry, the U.S. could benefit from the U.K. s 
experience in systematically and more honestly allocating health c�e 
resources.233 Although consolidation and · managed care are sig­
nificantly impacting both U.S. health care delivery and 
regulation,234 the U.S. system's no-concern-for-costs mentality is 
229 The skewed incentives that arise from the rate-setting aspect of the U.S. health care 
system have also been addressed in the ESRD case study discussed in note 222. See 
Kaserman, supra note 216, at 85. Kaserman noted that the Health Care Finance Ad­
ministration's "reimbursement rates are set on the basis of observed (audited) costs." Id. Each 
time the rates were adjusted, the incentive to lower costs would take over. See id. When the 
treatment was audited again, the rate would be lowered. See id. "This process of adjustment 
and readjustment by the clinics and the regulators creates a downward spiral of reimburse­
ment rates and quality of care." Id. Kaserman also noted that HFCA's practice of checking 
entry to the industry to provide the service as an indicator of adequate rate setting is not 
reliable, for those entering the industry may be offering substandard care. See id. at 86. 
"Consequently, observations on entry-or, for that matter, profitability-cannot be used to 
make inferences about the financial health of the industry in the absence of quality con­
siderations." Id. 
• :iao The absence of uniform guidelines has resulted in deference to providers, the private 
insurance sector, and to the courts to determine coverage. See Karen L. Illuzzi Gallinari, The 
State of the Law on Insurance Coverage for State of the Art Medical Treatments, 12 MEALEY'S Lmo. REP.: �AD FAITH 16 (1995) (discussing the use of specific exclusions to deny coverage). 
See, e.g. , Wilham P. Peters & Mark C. Rogers, Variation. in Approval by Insurance Companies of Coverage for Autologow Bone Marrow Transplantation. for Breast Cancer, 330 NEW ENG. J. MEO. 473, 476 (1994) (compiling data on decisions of whether or not to provide coverage for Autologous Bone Marrow Transplantation for breast cancer). 
231 See ORIENT, supra note 148, at 136-38. 
232 
.
The U.K. physicians' civil servant status may enable them to more objectively and effectively ass�ss the relative quality of advances in medical science and analyze costs and be:fits. See id; New Era, supra note 9, at 340 & nn.67-68. 234 See ORIENT, supra note 148, at 136-38. 
See New Era, supra note 9, at 331 & nn.1-4· Mark Kadzielski et al R R 
· nd n--t · G '-'·1· U-,.,- u al ' ., eer eview a �, u.: ice u...., ines •wer ne th Care Reform 16 Wm L (discussing the need for clinical practice guidelin�s as a re
:
�
:f the REV. 15� 157-�0 (199�) focus upon the cost and effectiveness of health care se-" 'dedmanage. care industry s ' -.ces provi to patients). 
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decades old.235 Relative to the U.K. and many other industrialized 
nations, the U.S. health care system generally lacks mechanisms for 
open, honest, and socially and professionally acceptable quality and 
cost-benefit assessment; rationing is taboo. 236 
While the U.S. health care system is now in a state of change,237 
and before the first full generation of biotechnology products reaches 
market, U.S. health care policy makers should consider and adopt 
modifications of the U.K.'s allocation and treatment mechanisms that 
have been effective. For example, the U.S. should examine the 
U.K.'s experience and success with treatment-coverage 
guidelines.  238 First, such an approach takes advantage of the 
235 See New Era, supra note 9, at 334-35 (noting that delivery of medical care has proceeded 
"without concern for costs"). 
236 See generally ORIENT, supra note 148 (discussing the inefficient practice in the U.S. 
health care system); DAVID U. HIMMELSTEIN & STEFFIE WOOLHANDLER, THE NATIONAL HEALTH 
PROGRAM BOOK ( 1994) (promoting a national health program that is comparable to the 
Canadian system); PEROT, supra note 216 (stressing the importance of Medicare and Medicaid 
for the U.S. health care system). 
237 See New Era, supra note 9, at 337 (stating that "[t)he advent of widespread managed 
care," acting in concert with "economic limitations" and "enhanced medical capabilities," has 
resulted in a "new approach to medical ethics"). See also, e.g., White, supra note 149, at 34 
(taking note of the federal government's effort to reform and reduce the cost of health care). 
238 See White, supra note 149, at 36-39 (referencing the higher reliance on treatment and 
other guidelines in the health care systems of other industrialized countries); Robert H. Brook, 
et al., Health System Reform and Quality, 276 JAMA 476, 476 (1996) ("Physicians should also 
use tools and guidelines both to coordinate care and to determine what care is to be provided 
in a population-based, multiprovider managed care system."); Sean Milmo, European Drug 
Sales are Up. (Pharmaceuticals '95), 248 CHEMICAL MARKETING REP. SR30 ( 1 995). France, 
Europe's biggest consumer of medicine, now is attempting to reduce use by "tightening" and 
"extending prescription guidelines for doctors." Id. The U.K. has developed guidelines for 
everything from standards for good practice to waiting times for outpatient therapy, to the 
appropriate uses of gene therapy. See UK Issues Guidelines for Gene Therapy, MARl<ETLETTER, 
Sept. 19, 1994; International Healthcare News, Bus. CONF. & MGMT. REP., Mar. 1 ,  1996, at 7 
(covering "new [U.K.] guidelines for health professionals on the management of waiting lists"). 
The use of peer review and guidelines in the U.S. health care system is addressed in New Era, 
supra note 9, at 352-53 & n.147; William M. Sage & James M. Jorling, A World that Won't 
Stand Still: Enterprise Liability by Private Contract, 43 DEPAUL L. REv. 1007, 1029-30 (1994); 
Kadzielski, supra note 234, at 157-60. At the present time, the U.S. is still experimenting and 
some efforts are already underway. See, e.g, ME. REV. STAT. ANN. tit. 24, §§ 2504-11 (West 
1990 & Supp. 1995) (establishing "professional competence committee[s]"). Perhaps the 
highest-profile federal efforts are the Acute Physiology and Chronic Evaluation system 
(APACHE), an experiment to standardize diagnosis and treatment through computerization, 
and the compilation and publication of two volumes of treatment guidelines based primarily 
on outcome� and e
_
ffectiveness of reseai:ch prepared by the Agency for Health Care Policy and 
Research with assistance from the Institutes of Medicine. See 42 U.S.C. §§ 299-299a-1 ( 1994). 
There also is precedent for international collaboration in constructing guidelines along the lines 
oft.he approach proposed in this Article. See, e.g. , C. Patterson & Larry W. Chambers, Preven­tative Jl_eal�h Care, LANCET, June 24, 1995, at 1611 (summarizing "clinical preventive health 
care gwdelmes [drawn up by expert panels in Canada, the U.S., and U.K] using an evidence-
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rtunity to modify and use practical and effectiv
e (meaning 
;��:en effective through practice) clinical guidelines dev
eloped in the 
U.K. through the expenditure of significant resources
.239 AIDS 
prevention guidelines are one illustration of how the U.S
. may 
benefit from such an approach. 240 Another example is guidelin
es 
for determining when comfort care is more appropriate than 
aggressive life-extending treatment.241 Second, comparative 
analysis could help U.S. public health officials to better understand 
the incentives and disincentives prevalent in both systems and 
improve health policy and regulation. Consider that doctors in the 
U.S. have been much more resistant to implementing prevention 
guidelines than their contemporaries in the U.K. and Canada.242 
Through IEL analysis, it may be possible to identify the reasons why 
U.S. physicians resist guidelines by identifying the relevant 
incentives and disincentives in both systems responsible for the 
difference in physician receptiveness to guidelines. The understand­
ing resulting from such analysis may enable the U.S. to construct 
mechanisms that utilize influential incentives to bring about the 
implementation of guidelines. As a result of such analysis, U.S. 
policy makers might decide to instill some of the health care 
professional and social norms from the U.K. system into their U.S. 
counterparts through changes in medical and public education. 
More fundamentally, an IEL approach would enable health care 
policy makers in both systems to share quality assessment data, and 
based approach . . . with strict attention to the quality of published trials"). 
239 Treatment guidelines have long been a part of the U.K.'s NHS system. Further, NHS 
is now l�unching an initiative to introduce more comprehensive quality assessment by, among 
other thmgs, expanding the input and decision making authority of providers who have the 
most direct contact with patients-namely nurses and social workers. In other words, NHS 
hopes to dismantle the current hierarchy and increase the influence of nurses and other 
providers who have the most contact with patients and their families over guideline drafting. 
See (BBC Broadcast, July 5, 1996 (aired in London)). 
240 See �icha�d A. Knox, Prevention Guide Set for US Doctors, BOSTON GLOBE, July 7, 1996, 
at 17, available in 1996 WL 6868362 (reporting that in July 1996, the U.S. adopted guidelines 
for AIDS prevention that urge doctors to talk to every patient about AIDS risks-guidelines 
Canada has had since 1988). 
24'. �e U.K. has extensive experience with openly providing comfort care (also called 
palhative care! at the end oflife, though the concept is new to the U.S. See Franklin G. Miller & Joseph J. Fms, A Proposal to Restructure Hospital Care for Dying Patients 334 NEW ENG J. MED. 1740, 1740 ( 1996). ' 
. 








one m five of those will modify their examining-room behavior in response. ; u.uwui>i..')r.r;IN & WOOLHANDLE . . R, supra note 236, at 91-119. See generally New Era, supra note 9 (discussing reasons why health care resources should be rationed). 
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it would give them the ability to coordinate efforts to compile 
necessary clinical information to fully assess new technologies. Such 
an approach, beyond being prudent in the short-run, is a necessary 
means to maximize resource allocation choices and benefits from the 
biotechnology products and capabilities that are being commer­
cialized and will continue to enter consumer markets in significant 
numbers well into the next millennium. 
V. CONCLUSION 
Biotechnology holds great promise for improving public health, and 
the U.S. and the U.K. have much to gain from the success of their 
biotechnology industries. However, each of these countries also face 
the daunting complications that accompany the commercialization of 
biotechnology. This Article has explored the status of the U.S. and 
the U.K. biotechnology industries and two major regulatory chal­
lenges: ( 1) to review and regulate a multitude of truly innovative 
genetic diagnostics and therapeutics to maximize public health 
benefits; and (2) to make the deluge of new health care capabilities 
available to those likely to benefit from them. 
The transnational nature of the biotechnology industry draws the 
U.S. and the U.K. together-just as the world's science community 
has been united through HGP. The miraculous advances in 
biomedical science of recent years could not have been accomplished 
without collaboration within the science community and between the 
science and industry sectors. Now the major world markets for 
pharmaceutical products are moving closer together through the 
establishment and work of the EMEA and domestic pressures on 
both the EMEA and the FDA. 
This Article has applied IEL to analyze regulatory dilemmas 
brought about by the commercialization of biotechnology. These are 
complications that must be confronted by public health officials in 
both the U.S. and the U.K. The central premise of this Article is 
that cooperation between the U.S. and the U.K. on the regulatory 
level will remove unnatural barriers between their national 
industrial sectors and will maxumze the talent and 
entrepreneurialism of both countries to best meet these challenges. 
Although the regulatory difficulties brought about by biotechnology 
may appear overwhelming, one only has to look at what has been 
accomplished in biomedical research and genetic medicine in recent 
years to realize that, through collaboration, they are surmountable. 
